Gene therapy: adenoviral vectors in clinical trial.
\\n\\n
More than half of the publishers listed alongside IntechOpen (18 out of 30) are Social Science and Humanities publishers. IntechOpen is an exception to this as a leader in not only Open Access content but Open Access content across all scientific disciplines, including Physical Sciences, Engineering and Technology, Health Sciences, Life Science, and Social Sciences and Humanities.
\\n\\nOur breakdown of titles published demonstrates this with 47% PET, 31% HS, 18% LS, and 4% SSH books published.
\\n\\n“Even though ItechOpen has shown the potential of sci-tech books using an OA approach,” other publishers “have shown little interest in OA books.”
\\n\\nAdditionally, each book published by IntechOpen contains original content and research findings.
\\n\\nWe are honored to be among such prestigious publishers and we hope to continue to spearhead that growth in our quest to promote Open Access as a true pioneer in OA book publishing.
\\n\\n\\n\\n
\\n"}]',published:!0,mainMedia:null},components:[{type:"htmlEditorComponent",content:'
Simba Information has released its Open Access Book Publishing 2020 - 2024 report and has again identified IntechOpen as the world’s largest Open Access book publisher by title count.
\n\nSimba Information is a leading provider for market intelligence and forecasts in the media and publishing industry. The report, published every year, provides an overview and financial outlook for the global professional e-book publishing market.
\n\nIntechOpen, De Gruyter, and Frontiers are the largest OA book publishers by title count, with IntechOpen coming in at first place with 5,101 OA books published, a good 1,782 titles ahead of the nearest competitor.
\n\nSince the first Open Access Book Publishing report published in 2016, IntechOpen has held the top stop each year.
\n\n\n\nMore than half of the publishers listed alongside IntechOpen (18 out of 30) are Social Science and Humanities publishers. IntechOpen is an exception to this as a leader in not only Open Access content but Open Access content across all scientific disciplines, including Physical Sciences, Engineering and Technology, Health Sciences, Life Science, and Social Sciences and Humanities.
\n\nOur breakdown of titles published demonstrates this with 47% PET, 31% HS, 18% LS, and 4% SSH books published.
\n\n“Even though ItechOpen has shown the potential of sci-tech books using an OA approach,” other publishers “have shown little interest in OA books.”
\n\nAdditionally, each book published by IntechOpen contains original content and research findings.
\n\nWe are honored to be among such prestigious publishers and we hope to continue to spearhead that growth in our quest to promote Open Access as a true pioneer in OA book publishing.
\n\n\n\n
\n'}],latestNews:[{slug:"intechopen-signs-new-contract-with-cepiec-china-for-distribution-of-open-access-books-20210319",title:"IntechOpen Signs New Contract with CEPIEC, China for Distribution of Open Access Books"},{slug:"150-million-downloads-and-counting-20210316",title:"150 Million Downloads and Counting"},{slug:"intechopen-secures-indefinite-content-preservation-with-clockss-20210309",title:"IntechOpen Secures Indefinite Content Preservation with CLOCKSS"},{slug:"intechopen-expands-to-all-global-amazon-channels-with-full-catalog-of-books-20210308",title:"IntechOpen Expands to All Global Amazon Channels with Full Catalog of Books"},{slug:"stanford-university-identifies-top-2-scientists-over-1-000-are-intechopen-authors-and-editors-20210122",title:"Stanford University Identifies Top 2% Scientists, Over 1,000 are IntechOpen Authors and Editors"},{slug:"intechopen-authors-included-in-the-highly-cited-researchers-list-for-2020-20210121",title:"IntechOpen Authors Included in the Highly Cited Researchers List for 2020"},{slug:"intechopen-maintains-position-as-the-world-s-largest-oa-book-publisher-20201218",title:"IntechOpen Maintains Position as the World’s Largest OA Book Publisher"},{slug:"all-intechopen-books-available-on-perlego-20201215",title:"All IntechOpen Books Available on Perlego"}]},book:{item:{type:"book",id:"1043",leadTitle:null,fullTitle:"Human Musculoskeletal Biomechanics",title:"Human Musculoskeletal Biomechanics",subtitle:null,reviewType:"peer-reviewed",abstract:"This book covers many aspects of human musculoskeletal biomechanics. As the title represents, aspects of forces, motion, kinetics, kinematics, deformation, stress, and strain are examined for a range of topics such as human muscles, skeleton, and vascular biomechanics independently or in the presence of devices. Topics range from image processing to interpret range of motion and/or diseases, to subject specific temporomandibular joint, spinal units, braces to control scoliosis, hand functions, spine anthropometric analyses along with finite element analyses. Therefore, this book will be valuable to students at introductory level to researchers at MS and PhD level searching for science of specific muscle/vascular to skeletal biomechanics. This book will be an ideal text to keep for graduate students in biomedical engineering since it is available for free, students may want to make use of this opportunity. Those that are interested to participate in the future edition of this book, on the same topic, as a contributor please feel free to contact the author.",isbn:null,printIsbn:"978-953-307-638-6",pdfIsbn:"978-953-51-6088-5",doi:"10.5772/1547",price:119,priceEur:129,priceUsd:155,slug:"human-musculoskeletal-biomechanics",numberOfPages:256,isOpenForSubmission:!1,isInWos:1,hash:"f35dcba453ef0c8f095a408a1e8a013d",bookSignature:"Tarun Goswami",publishedDate:"January 5th 2012",coverURL:"https://cdn.intechopen.com/books/images_new/1043.jpg",numberOfDownloads:54614,numberOfWosCitations:29,numberOfCrossrefCitations:16,numberOfDimensionsCitations:37,hasAltmetrics:0,numberOfTotalCitations:82,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"November 3rd 2010",dateEndSecondStepPublish:"December 1st 2010",dateEndThirdStepPublish:"April 7th 2011",dateEndFourthStepPublish:"May 7th 2011",dateEndFifthStepPublish:"July 6th 2011",currentStepOfPublishingProcess:5,indexedIn:"1,2,3,4,5,6,7",editedByType:"Edited by",kuFlag:!1,editors:[{id:"66583",title:"Dr.",name:"Tarun",middleName:null,surname:"Goswami",slug:"tarun-goswami",fullName:"Tarun Goswami",profilePictureURL:"https://mts.intechopen.com/storage/users/66583/images/1848_n.jpg",biography:"Dr. Tarun Goswami graduated with a Doctor of Science degree in Mechanical Engineering from Helsinki University of Technology. He worked in the aircraft industry before transitioning to academia. He currently holds a joint appointment of Associate Professor in Biomedical, Industrial and Human Factors Engineering and Orthopaedic Surgery, Sports Medicine and Rehabilitation, at Wright State University, Dayton, Ohio. He directs Orthopaedic Biomechanics Laboratory, Spinal Research Group and Device Development Center. Students from undergraduate, graduate, medical and residency programs work with him on a range of biomechanical topics. His research is supported by Air Force and Army and other orthopaedic related companies. He has published more than 75 papers in archival journals and numerous abstracts and presentations in conferences. For some of his works on total ankle replacement, total toe replacement, spinal disc replacement, fracture fixation devices, pacemaker lead designs and other topics patents are pending. He teaches such courses as Introduction to Biomedical Engineering, Biomechanics and Bioenergetics, Biomaterials, and Experimental Orthopaedic Engineering.",institutionString:null,position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"4",totalChapterViews:"0",totalEditedBooks:"2",institution:{name:"Wright State University",institutionURL:null,country:{name:"United States of America"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"686",title:"Biomechanics",slug:"engineering-biomedical-engineering-biomechanics"}],chapters:[{id:"21040",title:"A Task-Level Biomechanical Framework for Motion Analysis and Control Synthesis",doi:"10.5772/22417",slug:"a-task-level-biomechanical-framework-for-motion-analysis-and-control-synthesis",totalDownloads:2240,totalCrossrefCites:0,totalDimensionsCites:1,signatures:"Vincent De Sapio and Richard Chen",downloadPdfUrl:"/chapter/pdf-download/21040",previewPdfUrl:"/chapter/pdf-preview/21040",authors:[{id:"47676",title:"Dr.",name:"Vincent",surname:"De Sapio",slug:"vincent-de-sapio",fullName:"Vincent De Sapio"},{id:"77570",title:"Dr.",name:"Richard",surname:"Chen",slug:"richard-chen",fullName:"Richard Chen"}],corrections:null},{id:"21041",title:"European Braces for Conservative Scoliosis Treatment",doi:"10.5772/19509",slug:"european-braces-for-conservative-scoliosis-treatment",totalDownloads:6924,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Theodoros B. Grivas",downloadPdfUrl:"/chapter/pdf-download/21041",previewPdfUrl:"/chapter/pdf-preview/21041",authors:[{id:"35180",title:"Dr.",name:"Theodoros",surname:"Grivas",slug:"theodoros-grivas",fullName:"Theodoros Grivas"}],corrections:null},{id:"21042",title:"Motion Preservation and Shock Absorbing in Cervical and Lumbar Spine: A New Device for Anterior Cervical Arthroplasty, for Anterior or Posterior Lumbar Arthroplasty",doi:"10.5772/24577",slug:"motion-preservation-and-shock-absorbing-in-cervical-and-lumbar-spine-a-new-device-for-anterior-cervi",totalDownloads:2250,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Giuseppe Maida",downloadPdfUrl:"/chapter/pdf-download/21042",previewPdfUrl:"/chapter/pdf-preview/21042",authors:[{id:"58240",title:"Dr.",name:"Giuseppe",surname:"Maida",slug:"giuseppe-maida",fullName:"Giuseppe Maida"}],corrections:null},{id:"21043",title:"Biomechanical Characteristics of the Bone",doi:"10.5772/19690",slug:"biomechanical-characteristics-of-the-bone",totalDownloads:14385,totalCrossrefCites:10,totalDimensionsCites:23,signatures:"Antonia Dalla Pria Bankoff",downloadPdfUrl:"/chapter/pdf-download/21043",previewPdfUrl:"/chapter/pdf-preview/21043",authors:[{id:"35869",title:"Dr.",name:"Antonia",surname:"Bankoff",slug:"antonia-bankoff",fullName:"Antonia Bankoff"}],corrections:null},{id:"21044",title:"Biomechanical Studies on Hand Function in Rehabilitation",doi:"10.5772/21457",slug:"biomechanical-studies-on-hand-function-in-rehabilitation",totalDownloads:4472,totalCrossrefCites:1,totalDimensionsCites:2,signatures:"Sofia Brorsson",downloadPdfUrl:"/chapter/pdf-download/21044",previewPdfUrl:"/chapter/pdf-preview/21044",authors:[{id:"43158",title:"Dr.",name:"Sofia",surname:"Brorsson",slug:"sofia-brorsson",fullName:"Sofia Brorsson"}],corrections:null},{id:"21045",title:"Cervical Spine Anthropometric and Finite Element Biomechanical Analysis",doi:"10.5772/35524",slug:"cervical-spine-anthropometric-and-finite-element-biomechanical-analysis",totalDownloads:2270,totalCrossrefCites:3,totalDimensionsCites:5,signatures:"Susan Hueston, Mbulelo Makola, Isaac Mabe and Tarun Goswami",downloadPdfUrl:"/chapter/pdf-download/21045",previewPdfUrl:"/chapter/pdf-preview/21045",authors:[{id:"66583",title:"Dr.",name:"Tarun",surname:"Goswami",slug:"tarun-goswami",fullName:"Tarun Goswami"}],corrections:null},{id:"21046",title:"Biomechanics of the Temporomandibular Joint",doi:"10.5772/33702",slug:"biomechanics-of-the-temporomandibular-joint",totalDownloads:17315,totalCrossrefCites:2,totalDimensionsCites:6,signatures:"Shirish M. Ingawalé and Tarun Goswami",downloadPdfUrl:"/chapter/pdf-download/21046",previewPdfUrl:"/chapter/pdf-preview/21046",authors:[{id:"66583",title:"Dr.",name:"Tarun",surname:"Goswami",slug:"tarun-goswami",fullName:"Tarun Goswami"}],corrections:null},{id:"21047",title:"Design and Analysis of Key Components in the Nanoindentation and Scratch Test Device",doi:"10.5772/19564",slug:"design-and-analysis-of-key-components-in-the-nanoindentation-and-scratch-test-device",totalDownloads:2194,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Hongwei Zhao, Hu Huang, Jiabin Ji and Zhichao Ma",downloadPdfUrl:"/chapter/pdf-download/21047",previewPdfUrl:"/chapter/pdf-preview/21047",authors:[{id:"35374",title:"Prof.",name:"Hu",surname:"Huang",slug:"hu-huang",fullName:"Hu Huang"},{id:"53835",title:"Prof.",name:"Hongwei",surname:"Zhao",slug:"hongwei-zhao",fullName:"Hongwei Zhao"},{id:"53836",title:"Mr",name:"Zhichao",surname:"Ma",slug:"zhichao-ma",fullName:"Zhichao Ma"},{id:"53837",title:"Mr",name:"Jiabin",surname:"Ji",slug:"jiabin-ji",fullName:"Jiabin Ji"}],corrections:null},{id:"21048",title:"Elements of Vascular Mechanics",doi:"10.5772/23829",slug:"elements-of-vascular-mechanics",totalDownloads:2566,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Gyorgy L Nadasy",downloadPdfUrl:"/chapter/pdf-download/21048",previewPdfUrl:"/chapter/pdf-preview/21048",authors:[{id:"53930",title:"Prof.",name:"Gyorgy L.",surname:"Nadasy",slug:"gyorgy-l.-nadasy",fullName:"Gyorgy L. Nadasy"}],corrections:null}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},relatedBooks:[{type:"book",id:"2415",title:"Injury and Skeletal Biomechanics",subtitle:null,isOpenForSubmission:!1,hash:"d4b9545dc2fce0aede84f773ec95fe92",slug:"injury-and-skeletal-biomechanics",bookSignature:"Tarun Goswami",coverURL:"https://cdn.intechopen.com/books/images_new/2415.jpg",editedByType:"Edited by",editors:[{id:"66583",title:"Dr.",name:"Tarun",surname:"Goswami",slug:"tarun-goswami",fullName:"Tarun Goswami"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9575",title:"Recent Advances in Biomechanics",subtitle:null,isOpenForSubmission:!1,hash:"97edc53b612c683e4c79a995a9f379c0",slug:"recent-advances-in-biomechanics",bookSignature:"Redha Taiar",coverURL:"https://cdn.intechopen.com/books/images_new/9575.jpg",editedByType:"Edited by",editors:[{id:"81693",title:"Prof.",name:"Redha",surname:"Taiar",slug:"redha-taiar",fullName:"Redha Taiar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophanides",surname:"Theophile",slug:"theophanides-theophile",fullName:"Theophanides Theophile"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"314",title:"Regenerative Medicine and Tissue Engineering",subtitle:"Cells and Biomaterials",isOpenForSubmission:!1,hash:"bb67e80e480c86bb8315458012d65686",slug:"regenerative-medicine-and-tissue-engineering-cells-and-biomaterials",bookSignature:"Daniel Eberli",coverURL:"https://cdn.intechopen.com/books/images_new/314.jpg",editedByType:"Edited by",editors:[{id:"6495",title:"Dr.",name:"Daniel",surname:"Eberli",slug:"daniel-eberli",fullName:"Daniel Eberli"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"57",title:"Physics and Applications of Graphene",subtitle:"Experiments",isOpenForSubmission:!1,hash:"0e6622a71cf4f02f45bfdd5691e1189a",slug:"physics-and-applications-of-graphene-experiments",bookSignature:"Sergey Mikhailov",coverURL:"https://cdn.intechopen.com/books/images_new/57.jpg",editedByType:"Edited by",editors:[{id:"16042",title:"Dr.",name:"Sergey",surname:"Mikhailov",slug:"sergey-mikhailov",fullName:"Sergey Mikhailov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1373",title:"Ionic Liquids",subtitle:"Applications and Perspectives",isOpenForSubmission:!1,hash:"5e9ae5ae9167cde4b344e499a792c41c",slug:"ionic-liquids-applications-and-perspectives",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/1373.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],ofsBooks:[]},correction:{item:{id:"68990",slug:"erratum-application-of-design-for-manufacturing-and-assembly-development-of-a-multifeedstock-biodies",title:"Erratum - Application of Design for Manufacturing and Assembly: Development of a Multifeedstock Biodiesel Processor",doi:null,correctionPDFUrl:"https://cdn.intechopen.com/pdfs/68990.pdf",downloadPdfUrl:"/chapter/pdf-download/68990",previewPdfUrl:"/chapter/pdf-preview/68990",totalDownloads:null,totalCrossrefCites:null,bibtexUrl:"/chapter/bibtex/68990",risUrl:"/chapter/ris/68990",chapter:{id:"63204",slug:"application-of-design-for-manufacturing-and-assembly-development-of-a-multifeedstock-biodiesel-proce",signatures:"Ilesanmi Afolabi Daniyan and Khumbulani Mpofu",dateSubmitted:"March 15th 2018",dateReviewed:"July 9th 2018",datePrePublished:"November 5th 2018",datePublished:"January 3rd 2019",book:{id:"7460",title:"Applications of Design for Manufacturing and Assembly",subtitle:null,fullTitle:"Applications of Design for Manufacturing and Assembly",slug:"applications-of-design-for-manufacturing-and-assembly",publishedDate:"January 3rd 2019",bookSignature:"Ancuţa Păcurar",coverURL:"https://cdn.intechopen.com/books/images_new/7460.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"184794",title:"Dr.",name:"Ancuta Carmen",middleName:null,surname:"Păcurar",slug:"ancuta-carmen-pacurar",fullName:"Ancuta Carmen Păcurar"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"11921",title:"Prof.",name:"Khumbulani",middleName:null,surname:"Mpofu",fullName:"Khumbulani Mpofu",slug:"khumbulani-mpofu",email:"mpofuk@tut.ac.za",position:null,institution:{name:"Tshwane University of Technology",institutionURL:null,country:{name:"South Africa"}}},{id:"260269",title:"Dr.",name:"Ilesanmi Afolabi",middleName:null,surname:"Daniyan",fullName:"Ilesanmi Afolabi Daniyan",slug:"ilesanmi-afolabi-daniyan",email:"afolabiilesanmi@yahoo.com",position:null,institution:null}]}},chapter:{id:"63204",slug:"application-of-design-for-manufacturing-and-assembly-development-of-a-multifeedstock-biodiesel-proce",signatures:"Ilesanmi Afolabi Daniyan and Khumbulani Mpofu",dateSubmitted:"March 15th 2018",dateReviewed:"July 9th 2018",datePrePublished:"November 5th 2018",datePublished:"January 3rd 2019",book:{id:"7460",title:"Applications of Design for Manufacturing and Assembly",subtitle:null,fullTitle:"Applications of Design for Manufacturing and Assembly",slug:"applications-of-design-for-manufacturing-and-assembly",publishedDate:"January 3rd 2019",bookSignature:"Ancuţa Păcurar",coverURL:"https://cdn.intechopen.com/books/images_new/7460.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"184794",title:"Dr.",name:"Ancuta Carmen",middleName:null,surname:"Păcurar",slug:"ancuta-carmen-pacurar",fullName:"Ancuta Carmen Păcurar"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"11921",title:"Prof.",name:"Khumbulani",middleName:null,surname:"Mpofu",fullName:"Khumbulani Mpofu",slug:"khumbulani-mpofu",email:"mpofuk@tut.ac.za",position:null,institution:{name:"Tshwane University of Technology",institutionURL:null,country:{name:"South Africa"}}},{id:"260269",title:"Dr.",name:"Ilesanmi Afolabi",middleName:null,surname:"Daniyan",fullName:"Ilesanmi Afolabi Daniyan",slug:"ilesanmi-afolabi-daniyan",email:"afolabiilesanmi@yahoo.com",position:null,institution:null}]},book:{id:"7460",title:"Applications of Design for Manufacturing and Assembly",subtitle:null,fullTitle:"Applications of Design for Manufacturing and Assembly",slug:"applications-of-design-for-manufacturing-and-assembly",publishedDate:"January 3rd 2019",bookSignature:"Ancuţa Păcurar",coverURL:"https://cdn.intechopen.com/books/images_new/7460.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"184794",title:"Dr.",name:"Ancuta Carmen",middleName:null,surname:"Păcurar",slug:"ancuta-carmen-pacurar",fullName:"Ancuta Carmen Păcurar"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},ofsBook:{item:{type:"book",id:"8360",leadTitle:null,title:"Field Programmable Gate Arrays (FPGAs) II",subtitle:null,reviewType:"peer-reviewed",abstract:"This Edited Volume Field Programmable Gate Arrays (FPGAs) II is a collection of reviewed and relevant research chapters, offering a comprehensive overview of recent developments in the field of Computer and Information Science. The book comprises single chapters authored by various researchers and edited by an expert active in the Computer and Information Science research area. All chapters are complete in itself but united under a common research study topic. This publication aims at providing a thorough overview of the latest research efforts by international authors on Computer and Information Science, and open new possible research paths for further novel developments.",isbn:"978-1-83881-057-3",printIsbn:"978-1-83881-056-6",pdfIsbn:"978-1-83881-058-0",doi:"10.5772/intechopen.78489",price:119,priceEur:129,priceUsd:155,slug:"field-programmable-gate-arrays-fpgas-ii",numberOfPages:114,isOpenForSubmission:!1,hash:"07085e95809ecc33b1b87b531ab1024c",bookSignature:"George Dekoulis",publishedDate:"September 9th 2020",coverURL:"https://cdn.intechopen.com/books/images_new/8360.jpg",keywords:null,numberOfDownloads:1142,numberOfWosCitations:0,numberOfCrossrefCitations:0,numberOfDimensionsCitations:0,numberOfTotalCitations:0,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"June 6th 2019",dateEndSecondStepPublish:"August 27th 2019",dateEndThirdStepPublish:"October 26th 2019",dateEndFourthStepPublish:"January 14th 2020",dateEndFifthStepPublish:"March 14th 2020",remainingDaysToSecondStep:"2 years",secondStepPassed:!0,currentStepOfPublishingProcess:5,editedByType:"Edited by",kuFlag:!1,biosketch:null,coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"9833",title:"Prof.",name:"George",middleName:null,surname:"Dekoulis",slug:"george-dekoulis",fullName:"George Dekoulis",profilePictureURL:"https://mts.intechopen.com/storage/users/9833/images/system/9833.jfif",biography:"Prof. George Dekoulis received his PhD in Space Engineering and Communications from Lancaster University, UK, in 2007. He was awarded a First Class BEng (Hons) degree in Communications Engineering from De Montfort University, UK, in 2001. He has received several awards from the Science and Technology Facilities Council (STFC), the Engineering and Physical Sciences Research Council (EPSRC), and the Hudswell International Research Scholarship (IET). He is currently the Dean of the Faculty of Sciences and Technology at the American University of Cyprus (AUCY), Cyprus. He was previously a professor at the Aerospace Engineering Institute (AEI), Cyprus. Founder of the IEEE Aerospace and Electronic Systems Society (AESS), Cyprus. General chair of IEEE Aerospace Engineering Innovations 2019 (IEEE AEI 2019), Limassol, Cyprus. He has worked as a professor in Space Computing & Engineering at various departments, such as Space & Planetary Physics, Aeronautical and Space Engineering, Professional Flight, Robotics/Mechatronics & Mechanical Engineering, Computer Science & Engineering, and Electrical and Electronics Engineering. His research focuses on the design of reconfigurable Space Computing and Engineering Systems.",institutionString:"Aerospace Engineering Institute",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"4",totalChapterViews:"0",totalEditedBooks:"9",institution:null}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"739",title:"Electronic Circuits",slug:"electrical-and-electronic-engineering-electronic-circuits"}],chapters:[{id:"69787",title:"Real-Time FPGA-Based Systems to Remote Monitoring",slug:"real-time-fpga-based-systems-to-remote-monitoring",totalDownloads:311,totalCrossrefCites:0,authors:[{id:"287147",title:"Ph.D.",name:"J. Guadalupe",surname:"Velasquez",slug:"j.-guadalupe-velasquez",fullName:"J. Guadalupe Velasquez"},{id:"307460",title:"Dr.",name:"Outmane",surname:"Oubram",slug:"outmane-oubram",fullName:"Outmane Oubram"},{id:"307461",title:"Dr.",name:"Luis",surname:"Cisneros-Villalobos",slug:"luis-cisneros-villalobos",fullName:"Luis Cisneros-Villalobos"}]},{id:"68886",title:"Real-Time Echo State Network Based on FPGA and Its Applications",slug:"real-time-echo-state-network-based-on-fpga-and-its-applications",totalDownloads:177,totalCrossrefCites:0,authors:[{id:"301301",title:"Dr.",name:"Yongbo",surname:"Liao",slug:"yongbo-liao",fullName:"Yongbo Liao"}]},{id:"71280",title:"Flexible Baseband Modulator Architecture for Multi-Waveform 5G Communications",slug:"flexible-baseband-modulator-architecture-for-multi-waveform-5g-communications",totalDownloads:240,totalCrossrefCites:0,authors:[{id:"307961",title:"M.Sc.",name:"Mário Lopes",surname:"Ferreira",slug:"mario-lopes-ferreira",fullName:"Mário Lopes Ferreira"},{id:"307963",title:"Dr.",name:"João Canas",surname:"Ferreira",slug:"joao-canas-ferreira",fullName:"João Canas Ferreira"}]},{id:"71252",title:"An Efficient FPGA-Based Frequency Shifter for LTE/LTE-A Systems",slug:"an-efficient-fpga-based-frequency-shifter-for-lte-lte-a-systems",totalDownloads:220,totalCrossrefCites:0,authors:[{id:"309106",title:"M.Sc.",name:"Felipe A.P.",surname:"de Figueiredo",slug:"felipe-a.p.-de-figueiredo",fullName:"Felipe A.P. de Figueiredo"},{id:"328944",title:"Dr.",name:"Fabbryccio A.C.M.",surname:"Cardoso",slug:"fabbryccio-a.c.m.-cardoso",fullName:"Fabbryccio A.C.M. Cardoso"}]},{id:"71792",title:"VLSI Implementation of Medical Image Fusion Using DWT-PCA Algorithms",slug:"vlsi-implementation-of-medical-image-fusion-using-dwt-pca-algorithms",totalDownloads:195,totalCrossrefCites:0,authors:[{id:"310527",title:"Ph.D. Student",name:"Surya Prasada Rao",surname:"Borra",slug:"surya-prasada-rao-borra",fullName:"Surya Prasada Rao Borra"},{id:"310528",title:"Dr.",name:"Rajesh K.",surname:"Panakala",slug:"rajesh-k.-panakala",fullName:"Rajesh K. Panakala"},{id:"310529",title:"Dr.",name:"Pullakura Rajesh",surname:"Kumar",slug:"pullakura-rajesh-kumar",fullName:"Pullakura Rajesh Kumar"}]}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"287827",firstName:"Gordan",lastName:"Tot",middleName:null,title:"Mr.",imageUrl:"https://mts.intechopen.com/storage/users/287827/images/8493_n.png",email:"gordan@intechopen.com",biography:"As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"6003",title:"Robotics",subtitle:"Legal, Ethical and Socioeconomic Impacts",isOpenForSubmission:!1,hash:"15ab11f5bb5aac89956dd8b42f261011",slug:"robotics-legal-ethical-and-socioeconomic-impacts",bookSignature:"George Dekoulis",coverURL:"https://cdn.intechopen.com/books/images_new/6003.jpg",editedByType:"Edited by",editors:[{id:"9833",title:"Prof.",name:"George",surname:"Dekoulis",slug:"george-dekoulis",fullName:"George Dekoulis"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5597",title:"Field",subtitle:"Programmable Gate Array",isOpenForSubmission:!1,hash:"ee9b6139297123dec4d906c950913c0d",slug:"field-programmable-gate-array",bookSignature:"George Dekoulis",coverURL:"https://cdn.intechopen.com/books/images_new/5597.jpg",editedByType:"Edited by",editors:[{id:"9833",title:"Prof.",name:"George",surname:"Dekoulis",slug:"george-dekoulis",fullName:"George Dekoulis"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8613",title:"Aerospace Engineering",subtitle:null,isOpenForSubmission:!1,hash:"075278075d72ebe02490ff58675119ef",slug:"aerospace-engineering",bookSignature:"George Dekoulis",coverURL:"https://cdn.intechopen.com/books/images_new/8613.jpg",editedByType:"Edited by",editors:[{id:"9833",title:"Prof.",name:"George",surname:"Dekoulis",slug:"george-dekoulis",fullName:"George Dekoulis"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6465",title:"Drones",subtitle:"Applications",isOpenForSubmission:!1,hash:"50a345acb86d524f7a505e09d1f2fc49",slug:"drones-applications",bookSignature:"George Dekoulis",coverURL:"https://cdn.intechopen.com/books/images_new/6465.jpg",editedByType:"Edited by",editors:[{id:"9833",title:"Prof.",name:"George",surname:"Dekoulis",slug:"george-dekoulis",fullName:"George Dekoulis"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8588",title:"Military Engineering",subtitle:null,isOpenForSubmission:!1,hash:"03399bdb07c21c27150ee424106395e2",slug:"military-engineering",bookSignature:"George Dekoulis",coverURL:"https://cdn.intechopen.com/books/images_new/8588.jpg",editedByType:"Edited by",editors:[{id:"9833",title:"Prof.",name:"George",surname:"Dekoulis",slug:"george-dekoulis",fullName:"George Dekoulis"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7414",title:"Modulation in Electronics and Telecommunications",subtitle:null,isOpenForSubmission:!1,hash:"5066fa20239d3de3ca87b3c45c680d01",slug:"modulation-in-electronics-and-telecommunications",bookSignature:"George Dekoulis",coverURL:"https://cdn.intechopen.com/books/images_new/7414.jpg",editedByType:"Edited by",editors:[{id:"9833",title:"Prof.",name:"George",surname:"Dekoulis",slug:"george-dekoulis",fullName:"George Dekoulis"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6864",title:"Autonomous Vehicles",subtitle:null,isOpenForSubmission:!1,hash:"c320902fc1cfc252c1db006b944996fb",slug:"autonomous-vehicles",bookSignature:"George Dekoulis",coverURL:"https://cdn.intechopen.com/books/images_new/6864.jpg",editedByType:"Edited by",editors:[{id:"9833",title:"Prof.",name:"George",surname:"Dekoulis",slug:"george-dekoulis",fullName:"George Dekoulis"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6350",title:"Space Flight",subtitle:null,isOpenForSubmission:!1,hash:"023c9b0d77a58c0a263c075a7deed7e5",slug:"space-flight",bookSignature:"George Dekoulis",coverURL:"https://cdn.intechopen.com/books/images_new/6350.jpg",editedByType:"Edited by",editors:[{id:"9833",title:"Prof.",name:"George",surname:"Dekoulis",slug:"george-dekoulis",fullName:"George Dekoulis"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3563",title:"Advanced Microwave Circuits and Systems",subtitle:null,isOpenForSubmission:!1,hash:"2d0a7e4bb67e54ab0bbe098ebb9537d4",slug:"advanced-microwave-circuits-and-systems",bookSignature:"Vitaliy Zhurbenko",coverURL:"https://cdn.intechopen.com/books/images_new/3563.jpg",editedByType:"Edited by",editors:[{id:"3721",title:"Prof.",name:"Vitaliy",surname:"Zhurbenko",slug:"vitaliy-zhurbenko",fullName:"Vitaliy Zhurbenko"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3576",title:"Solid State Circuits Technologies",subtitle:null,isOpenForSubmission:!1,hash:"a14e0865ac126e0234df9b53a5943ebf",slug:"solid-state-circuits-technologies",bookSignature:"Jacobus W. Swart",coverURL:"https://cdn.intechopen.com/books/images_new/3576.jpg",editedByType:"Edited by",editors:[{id:"5235",title:"Professor",name:"Jacobus",surname:"Swart",slug:"jacobus-swart",fullName:"Jacobus Swart"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"24628",title:"Inhibitors of Proteinases as Potential Anti-Cancer Agents",doi:"10.5772/27713",slug:"inhibitors-of-proteinases-as-potential-anti-cancer-agents",body:null,keywords:null,chapterPDFUrl:"https://cdn.intechopen.com/pdfs/24628.pdf",chapterXML:null,downloadPdfUrl:"/chapter/pdf-download/24628",previewPdfUrl:"/chapter/pdf-preview/24628",totalDownloads:2384,totalViews:98,totalCrossrefCites:1,totalDimensionsCites:2,hasAltmetrics:0,dateSubmitted:"February 21st 2011",dateReviewed:"July 4th 2011",datePrePublished:null,datePublished:"December 7th 2011",dateFinished:null,readingETA:"0",abstract:null,reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/24628",risUrl:"/chapter/ris/24628",book:{slug:"drug-development-a-case-study-based-insight-into-modern-strategies"},signatures:"Karolina Gluza and Paweł Kafarski",authors:[{id:"71234",title:"Dr.",name:"Pawel",middleName:null,surname:"Kafarski",fullName:"Pawel Kafarski",slug:"pawel-kafarski",email:"pawel.kafarski@pwr.wroc.pl",position:null,institution:{name:"Wrocław University of Technology",institutionURL:null,country:{name:"Poland"}}},{id:"77536",title:"Mrs.",name:"Gluza",middleName:null,surname:"Karolina",fullName:"Gluza Karolina",slug:"gluza-karolina",email:"karolina.gluza@pwr.wroc.pl",position:null,institution:{name:"Wrocław University of Technology",institutionURL:null,country:{name:"Poland"}}}],sections:null,chapterReferences:null,footnotes:null,contributors:null,corrections:null},book:{id:"2025",title:"Drug Development",subtitle:"A Case Study Based Insight into Modern Strategies",fullTitle:"Drug Development - A Case Study Based Insight into Modern Strategies",slug:"drug-development-a-case-study-based-insight-into-modern-strategies",publishedDate:"December 7th 2011",bookSignature:"Chris Rundfeldt",coverURL:"https://cdn.intechopen.com/books/images_new/2025.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",isbn:null,printIsbn:"978-953-307-257-9",pdfIsbn:"978-953-51-4392-5",editors:[{id:"88412",title:"Dr.",name:"Chris",middleName:null,surname:"Rundfeldt",slug:"chris-rundfeldt",fullName:"Chris Rundfeldt"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"24626",title:"Discovery and Optimization of Inhibitors of DNA Methyltransferase as Novel Drugs for Cancer Therapy",slug:"discovery-and-optimization-of-inhibitors-of-dna-methyltransferase-as-novel-drugs-for-cancer-therapy",totalDownloads:3489,totalCrossrefCites:5,signatures:"Jakyung Yoo and José L. Medina-Franco",authors:[{id:"71346",title:"Dr.",name:"Jose",middleName:"L",surname:"Medina-Franco",fullName:"Jose Medina-Franco",slug:"jose-medina-franco"},{id:"110672",title:"Dr.",name:"Jakyung",middleName:null,surname:"Yoo",fullName:"Jakyung Yoo",slug:"jakyung-yoo"}]},{id:"24627",title:"Development of Novel Secondary Hormonal Therapies for Castrate-Resistant Prostate Cancer",slug:"development-of-novel-secondary-hormonal-therapies-for-castrate-resistant-prostate-cancer",totalDownloads:2014,totalCrossrefCites:0,signatures:"Rahul Aggarwal and Charles J. Ryan",authors:[{id:"71942",title:"Dr.",name:"Charles",middleName:null,surname:"Ryan",fullName:"Charles Ryan",slug:"charles-ryan"},{id:"79984",title:"Dr.",name:"Rahul",middleName:null,surname:"Aggarwal",fullName:"Rahul Aggarwal",slug:"rahul-aggarwal"}]},{id:"24628",title:"Inhibitors of Proteinases as Potential Anti-Cancer Agents",slug:"inhibitors-of-proteinases-as-potential-anti-cancer-agents",totalDownloads:2384,totalCrossrefCites:1,signatures:"Karolina Gluza and Paweł Kafarski",authors:[{id:"71234",title:"Dr.",name:"Pawel",middleName:null,surname:"Kafarski",fullName:"Pawel Kafarski",slug:"pawel-kafarski"},{id:"77536",title:"Mrs.",name:"Gluza",middleName:null,surname:"Karolina",fullName:"Gluza Karolina",slug:"gluza-karolina"}]},{id:"24629",title:"Histamine Receptors as Potential Therapeutic Targets for Cancer Drug Development",slug:"histamine-receptors-as-potential-therapeutic-targets-for-cancer-drug-development",totalDownloads:3638,totalCrossrefCites:1,signatures:"Vanina A. Medina, Diego J. Martinel Lamas, Pablo G. Brenzoni, Noelia Massari, Eliana Carabajal and Elena S. Rivera",authors:[{id:"56309",title:"Prof.",name:"Elena",middleName:null,surname:"Rivera",fullName:"Elena Rivera",slug:"elena-rivera"}]},{id:"24630",title:"Histone Deacetylase Inhibitors as Therapeutic Agents for Cancer Therapy: Drug Metabolism and Pharmacokinetic Properties",slug:"histone-deacetylase-inhibitors-as-therapeutic-agents-for-cancer-therapy-drug-metabolism-and-pharmaco",totalDownloads:4772,totalCrossrefCites:2,signatures:"Ethirajulu Kantharaj and Ramesh Jayaraman",authors:[{id:"71581",title:"Dr",name:null,middleName:null,surname:"Kantharaj",fullName:"Kantharaj",slug:"kantharaj"},{id:"125501",title:"Mr.",name:"Ramesh",middleName:null,surname:"Jayaraman",fullName:"Ramesh Jayaraman",slug:"ramesh-jayaraman"}]},{id:"24631",title:"Antimicrobial Peptides: New Frontiers in the Therapy of Infections",slug:"antimicrobial-peptides-new-frontiers-in-the-therapy-of-infections",totalDownloads:4862,totalCrossrefCites:1,signatures:"Mario Zucca, Sara Scutera and Dianella Savoia",authors:[{id:"77294",title:"Dr.",name:"Dianella",middleName:null,surname:"Savoia",fullName:"Dianella Savoia",slug:"dianella-savoia"}]},{id:"24632",title:"microRNAs as Therapeutic Targets to Combat Diverse Human Diseases",slug:"micrornas-as-therapeutic-targets-to-combat-diverse-human-diseases",totalDownloads:1763,totalCrossrefCites:1,signatures:"Elizabeth Hong-Geller and Nan Li",authors:[{id:"68491",title:"Dr.",name:"Elizabeth",middleName:null,surname:"Hong-Geller",fullName:"Elizabeth Hong-Geller",slug:"elizabeth-hong-geller"},{id:"79196",title:"Dr.",name:"Nan",middleName:null,surname:"Li",fullName:"Nan Li",slug:"nan-li"}]},{id:"24633",title:"Potentiation of Available Antibiotics by Targeting Resistance – An Emerging Trend in Tuberculosis Drug Development",slug:"potentiation-of-available-antibiotics-by-targeting-resistance-an-emerging-trend-in-tuberculosis-drug",totalDownloads:2201,totalCrossrefCites:0,signatures:"Kerstin A. Wolff, Marissa Sherman and Liem Nguyen",authors:[{id:"71171",title:"Prof.",name:"Liem",middleName:null,surname:"Nguyen",fullName:"Liem Nguyen",slug:"liem-nguyen"},{id:"77484",title:"Ms.",name:"Marissa",middleName:null,surname:"Sherman",fullName:"Marissa Sherman",slug:"marissa-sherman"},{id:"77485",title:"Ms.",name:"Kerstin",middleName:"Andrea",surname:"Wolff",fullName:"Kerstin Wolff",slug:"kerstin-wolff"}]},{id:"24634",title:"Antitubercular Drugs Development: Recent Advances in Selected Therapeutic Targets and Rational Drug Design",slug:"antitubercular-drugs-development-recent-advances-in-selected-therapeutic-targets-and-rational-drug-d",totalDownloads:8271,totalCrossrefCites:1,signatures:"Virgilio Bocanegra-García, Abraham García, Jose Prisco Palma-Nicolás, Isidro Palos and Gildardo Rivera",authors:[{id:"71323",title:"Prof.",name:"Gildardo",middleName:null,surname:"Rivera",fullName:"Gildardo Rivera",slug:"gildardo-rivera"},{id:"80629",title:"Dr.",name:"Virgilio",middleName:null,surname:"Bocanegra-Garcia",fullName:"Virgilio Bocanegra-Garcia",slug:"virgilio-bocanegra-garcia"},{id:"80631",title:"Prof.",name:"Abraham",middleName:null,surname:"Garcia",fullName:"Abraham Garcia",slug:"abraham-garcia"},{id:"80632",title:"Dr.",name:"Isidro",middleName:null,surname:"Palos",fullName:"Isidro Palos",slug:"isidro-palos"},{id:"125606",title:"Dr.",name:"Jose Prisco",middleName:null,surname:"Palma-Nicolas",fullName:"Jose Prisco Palma-Nicolas",slug:"jose-prisco-palma-nicolas"}]},{id:"24635",title:"Insight into the Key Structural Features of Potent Enoyl Acyl Carrier Protein Reductase Inhibitors Based on Computer Aided Molecular Design",slug:"insight-into-the-key-structural-features-of-potent-enoyl-acyl-carrier-protein-reductase-inhibitors-b",totalDownloads:1978,totalCrossrefCites:0,signatures:"Auradee Punkvang, Pharit Kamsri, Kodchakon Kun-asa, Patchreenart Saparpakorn, Supa Hannongbua, Peter Wolschann and Pornpan Pungpo",authors:[{id:"72104",title:"Dr.",name:"Pornpan",middleName:null,surname:"Pungpo",fullName:"Pornpan Pungpo",slug:"pornpan-pungpo"},{id:"80007",title:"Dr.",name:"Auradee",middleName:null,surname:"Punkvang",fullName:"Auradee Punkvang",slug:"auradee-punkvang"},{id:"80008",title:"Mr.",name:"Parit",middleName:null,surname:"Khumsri",fullName:"Parit Khumsri",slug:"parit-khumsri"},{id:"80011",title:"Dr.",name:"Patchreenart",middleName:null,surname:"Saparpakorn",fullName:"Patchreenart Saparpakorn",slug:"patchreenart-saparpakorn"},{id:"80012",title:"Prof.",name:"Supa",middleName:null,surname:"Hannongbua",fullName:"Supa Hannongbua",slug:"supa-hannongbua"},{id:"80013",title:"Prof.",name:"Peter",middleName:null,surname:"Wolschann",fullName:"Peter Wolschann",slug:"peter-wolschann"},{id:"123205",title:"Ms.",name:"Kodchakon",middleName:null,surname:"Kun-Asa",fullName:"Kodchakon Kun-Asa",slug:"kodchakon-kun-asa"}]},{id:"24636",title:"RNA Interference-Based Therapeutics: Harnessing the Powers of Nature",slug:"rna-interference-based-therapeutics-harnessing-the-powers-of-nature",totalDownloads:2281,totalCrossrefCites:1,signatures:"Tamara Martinez, Natalia Wright, Covadonga Paneda, Ana I. Jimenez and Marta Lopez-Fraga",authors:[{id:"78427",title:"Dr.",name:"Marta",middleName:null,surname:"Lopez-Fraga",fullName:"Marta Lopez-Fraga",slug:"marta-lopez-fraga"},{id:"104927",title:"Dr.",name:"Covadonga",middleName:null,surname:"Paneda",fullName:"Covadonga Paneda",slug:"covadonga-paneda"},{id:"104929",title:"Dr.",name:"Natalia",middleName:null,surname:"Wright",fullName:"Natalia Wright",slug:"natalia-wright"},{id:"104931",title:"Dr.",name:"Tamara",middleName:null,surname:"Martinez",fullName:"Tamara Martinez",slug:"tamara-martinez"},{id:"104934",title:"Dr.",name:"Ana I.",middleName:null,surname:"Jimenez",fullName:"Ana I. Jimenez",slug:"ana-i.-jimenez"}]},{id:"24637",title:"P2X Receptors as New Therapeutic Targets",slug:"p2x-receptors-as-new-therapeutic-targets",totalDownloads:3843,totalCrossrefCites:0,signatures:"Liang Xin, Xiao Yanjuan and Li Zhiyuan",authors:[{id:"68562",title:"Prof.",name:"Zhiyuan",middleName:null,surname:"Li",fullName:"Zhiyuan Li",slug:"zhiyuan-li"},{id:"120654",title:"Dr.",name:"Xin",middleName:null,surname:"Liang",fullName:"Xin Liang",slug:"xin-liang"},{id:"120655",title:"MSc.",name:"Yajuan",middleName:null,surname:"Xiao",fullName:"Yajuan Xiao",slug:"yajuan-xiao"}]},{id:"24638",title:"Pregnane X Receptor in Drug Development",slug:"pregnane-x-receptor-in-drug-development",totalDownloads:4136,totalCrossrefCites:0,signatures:"Su Sien Ong, Yue-Ming Wang, Sergio C. Chai and Taosheng Chen",authors:[{id:"71406",title:"Dr.",name:"Taosheng",middleName:null,surname:"Chen",fullName:"Taosheng Chen",slug:"taosheng-chen"},{id:"120802",title:"Dr.",name:"Su Sien",middleName:null,surname:"Ong",fullName:"Su Sien Ong",slug:"su-sien-ong"},{id:"120803",title:"Dr.",name:"Yue-Ming",middleName:null,surname:"Wang",fullName:"Yue-Ming Wang",slug:"yue-ming-wang"},{id:"120804",title:"Dr.",name:"Sergio",middleName:"C.",surname:"Chai",fullName:"Sergio Chai",slug:"sergio-chai"}]},{id:"24639",title:"Crosstalk Between the Immune and Central Nervous Systems with Special Reference to Drug Development",slug:"crosstalk-between-the-immune-and-central-nervous-systems-with-special-reference-to-drug-development",totalDownloads:1908,totalCrossrefCites:0,signatures:"Takekazu Kubo, Shigeru Tokita and Toshihide Yamashita",authors:[{id:"76368",title:"Dr.",name:"Takekazu",middleName:null,surname:"Kubo",fullName:"Takekazu Kubo",slug:"takekazu-kubo"}]},{id:"24640",title:"Liquiritigenin Attenuates Alzheimer’s-Like Neuropathology in an Amyloid Protein Precursor Transgenic Mouse Model and the Underlying Mechanisms",slug:"liquiritigenin-attenuates-alzheimer-s-like-neuropathology-in-an-amyloid-protein-precursor-transgenic",totalDownloads:1895,totalCrossrefCites:0,signatures:"Rui Ting Liu, Jin Tian Tang, Li Bo Zou, Jie Ying Fu and Qiu Jun Lu",authors:[{id:"72120",title:"Dr",name:null,middleName:null,surname:"Lu",fullName:"Lu",slug:"lu"},{id:"73305",title:"Dr.",name:"Ruiting",middleName:null,surname:"Liu",fullName:"Ruiting Liu",slug:"ruiting-liu"}]},{id:"24641",title:"Novel Therapeutic Strategies for Chagas` Disease",slug:"novel-therapeutic-strategies-for-chagas-disease",totalDownloads:2911,totalCrossrefCites:0,signatures:"Alane Beatriz Vermelho, Carlos Alberto Manssour Fraga, Samir Aquino Carvalho, Edson Ferreira da Silva, Solange Lisboa de Castro, Igor de Almeida Rodrigues, Maria do Socorro dos Santos Rosa, Ana Claudia Fernandes Amaral and Giseli Capaci Rodrigues",authors:[{id:"80376",title:"Dr.",name:"Alane Beatriz",middleName:null,surname:"Vermelho",fullName:"Alane Beatriz Vermelho",slug:"alane-beatriz-vermelho"}]},{id:"24642",title:"The Gut Microbiota as Target for Innovative Drug Development: Perspectives and a Case Study of Inflammatory Bowel Diseases",slug:"the-gut-microbiota-as-target-for-innovative-drug-development-perspectives-and-a-case-study-of-inflam",totalDownloads:3064,totalCrossrefCites:1,signatures:"Joan Vermeiren, Sam Possemiers, Massimo Marzorati and Tom Van de Wiele",authors:[{id:"72020",title:"Dr.",name:"Sam",middleName:null,surname:"Possemiers",fullName:"Sam Possemiers",slug:"sam-possemiers"},{id:"119656",title:"MSc.",name:"Joan",middleName:null,surname:"Vermeiren",fullName:"Joan Vermeiren",slug:"joan-vermeiren"},{id:"120348",title:"Dr.",name:"Massimo",middleName:null,surname:"Marzorati",fullName:"Massimo Marzorati",slug:"massimo-marzorati"},{id:"120350",title:"Prof.",name:"Tom",middleName:null,surname:"Van De Wiele",fullName:"Tom Van De Wiele",slug:"tom-van-de-wiele"}]},{id:"24643",title:"Endophytic Fungi of Tropical Forests: A Promising Source of Bioactive Prototype Molecules for the Treatment of Neglected Diseases",slug:"endophytic-fungi-of-tropical-forests-a-promising-source-of-bioactive-prototype-molecules-for-the-tre",totalDownloads:4499,totalCrossrefCites:1,signatures:"Luiz H. Rosa, Mariana L.A. Vieira, Betania B. Cota, Susana Johann,Tânia M.A. Alves, Carlos L. Zani and Carlos A. Rosa",authors:[{id:"62658",title:"Dr.",name:"Carlos",middleName:null,surname:"Rosa",fullName:"Carlos Rosa",slug:"carlos-rosa"},{id:"71522",title:"Dr.",name:"Luiz",middleName:null,surname:"Rosa",fullName:"Luiz Rosa",slug:"luiz-rosa"},{id:"79635",title:"MSc.",name:"Mariana",middleName:null,surname:"Marianalavieira",fullName:"Mariana Marianalavieira",slug:"mariana-marianalavieira"},{id:"79636",title:"Dr.",name:"Susana",middleName:null,surname:"Johann",fullName:"Susana Johann",slug:"susana-johann"},{id:"79637",title:"Dr.",name:"Tania",middleName:null,surname:"Alves",fullName:"Tania Alves",slug:"tania-alves"},{id:"79638",title:"Dr.",name:"Carlos",middleName:null,surname:"Zani",fullName:"Carlos Zani",slug:"carlos-zani"}]},{id:"24644",title:"Bioproduction of Depsidones for Pharmaceutical Purposes",slug:"bioproduction-of-depsidones-for-pharmaceutical-purposes",totalDownloads:2809,totalCrossrefCites:0,signatures:"María Estrella Legaz, Roberto de Armas and Carlos Vicente",authors:[{id:"68681",title:"Prof.",name:"Carlos",middleName:null,surname:"Vicente",fullName:"Carlos Vicente",slug:"carlos-vicente"}]},{id:"24645",title:"Multi-Dose Container for Nasal and Ophthalmic Drugs: A Preservative Free Future?",slug:"multi-dose-container-for-nasal-and-ophthalmic-drugs-a-preservative-free-future-",totalDownloads:5473,totalCrossrefCites:2,signatures:"Degenhard Marx and Matthias Birkhoff",authors:[{id:"71452",title:"Dr.",name:"Degenhard",middleName:null,surname:"Marx",fullName:"Degenhard Marx",slug:"degenhard-marx"},{id:"72854",title:"Mr.",name:"Matthias",middleName:null,surname:"Birkhoff",fullName:"Matthias Birkhoff",slug:"matthias-birkhoff"}]},{id:"24646",title:"Microneedle-Assisted Transdermal Delivery of Opioid Antagonists for the Treatment of Alcoholism",slug:"microneedle-assisted-transdermal-delivery-of-opioid-antagonists-for-the-treatment-of-alcoholism",totalDownloads:2353,totalCrossrefCites:0,signatures:"Stan L. Banks, Audra L. Stinchcomb and Kalpana S. Paudel",authors:[{id:"88287",title:"Dr.",name:"Kalpana",middleName:null,surname:"Paudel",fullName:"Kalpana Paudel",slug:"kalpana-paudel"},{id:"88295",title:"Dr.",name:"Stan",middleName:null,surname:"Banks",fullName:"Stan Banks",slug:"stan-banks"},{id:"88297",title:"Dr.",name:"Audra",middleName:null,surname:"Stinchcomb",fullName:"Audra Stinchcomb",slug:"audra-stinchcomb"}]},{id:"24647",title:"Innovative Proposals for Incentivizing Drug Development",slug:"innovative-proposals-for-incentivizing-drug-development",totalDownloads:1982,totalCrossrefCites:0,signatures:"Kristina M. Lybecker",authors:[{id:"76892",title:"Dr.",name:"Kristina",middleName:null,surname:"Lybecker",fullName:"Kristina Lybecker",slug:"kristina-lybecker"}]},{id:"24648",title:"Drug Experimentation in Healthy Volunteers",slug:"drug-experimentation-in-healthy-volunteers",totalDownloads:5130,totalCrossrefCites:0,signatures:"Giovanni Gori, Giuseppe Pasqualetti, Catia Castiglioni, Corrado Blandizzi and Mario Del Tacca",authors:[{id:"72070",title:"Prof.",name:"Mario",middleName:null,surname:"Del Tacca",fullName:"Mario Del Tacca",slug:"mario-del-tacca"},{id:"80278",title:"Dr.",name:"Giovanni",middleName:null,surname:"Gori",fullName:"Giovanni Gori",slug:"giovanni-gori"},{id:"80280",title:"Dr.",name:"Giuseppe",middleName:null,surname:"Pasqualetti",fullName:"Giuseppe Pasqualetti",slug:"giuseppe-pasqualetti"},{id:"80283",title:"Prof.",name:"Corrado",middleName:null,surname:"Blandizzi",fullName:"Corrado Blandizzi",slug:"corrado-blandizzi"},{id:"122001",title:"Dr.",name:"Catia",middleName:null,surname:"Castiglioni",fullName:"Catia Castiglioni",slug:"catia-castiglioni"}]},{id:"24649",title:"Changes in Research and Development of Medicinal Products since the Paediatric Regulation",slug:"changes-in-research-and-development-of-medicinal-products-since-the-paediatric-regulation",totalDownloads:3030,totalCrossrefCites:0,signatures:"Adriana Ceci, Mariana Catapano, Cristina Manfredi, Ian Wong, Mine Orlu-Gul, Annarita Meneguz, Paola Baiardi, Oscar Della Pasqua, Achille Iolascon, Maurizio Scarpa and Antje Neubert",authors:[{id:"75385",title:"Prof.",name:"Adriana",middleName:null,surname:"Ceci",fullName:"Adriana Ceci",slug:"adriana-ceci"},{id:"80175",title:"Dr.",name:"Mariana",middleName:null,surname:"Catapano",fullName:"Mariana Catapano",slug:"mariana-catapano"},{id:"80178",title:"Prof.",name:"Ian",middleName:null,surname:"Wong",fullName:"Ian Wong",slug:"ian-wong"},{id:"80182",title:"Prof.",name:"Annarita",middleName:null,surname:"Meneguz",fullName:"Annarita Meneguz",slug:"annarita-meneguz"},{id:"80184",title:"Dr.",name:"Paola",middleName:null,surname:"Baiardi",fullName:"Paola Baiardi",slug:"paola-baiardi"},{id:"80186",title:"Dr.",name:"Oscar",middleName:null,surname:"Della Pasqua",fullName:"Oscar Della Pasqua",slug:"oscar-della-pasqua"},{id:"120441",title:"Dr.",name:"Achille",middleName:null,surname:"Iolascon",fullName:"Achille Iolascon",slug:"achille-iolascon"},{id:"120442",title:"Dr.",name:"Antje",middleName:null,surname:"Neubert",fullName:"Antje Neubert",slug:"antje-neubert"}]}]},relatedBooks:[{type:"book",id:"5360",title:"Special Topics in Drug Discovery",subtitle:null,isOpenForSubmission:!1,hash:"db7d4ff92690f87b26f5585c8999ce20",slug:"special-topics-in-drug-discovery",bookSignature:"Taosheng Chen and Sergio C. Chai",coverURL:"https://cdn.intechopen.com/books/images_new/5360.jpg",editedByType:"Edited by",editors:[{id:"71406",title:"Dr.",name:"Taosheng",surname:"Chen",slug:"taosheng-chen",fullName:"Taosheng Chen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"52249",title:"Autobioluminescent Cellular Models for Enhanced Drug Discovery",slug:"autobioluminescent-cellular-models-for-enhanced-drug-discovery",signatures:"Tingting Xu, Michael Conway, Ashley Frank, Amelia Brumbaugh,\nSteven Ripp and Dan Close",authors:[{id:"34168",title:"Dr.",name:"Steven",middleName:null,surname:"Ripp",fullName:"Steven Ripp",slug:"steven-ripp"},{id:"89407",title:"Dr.",name:"Tingting",middleName:null,surname:"Xu",fullName:"Tingting Xu",slug:"tingting-xu"},{id:"187444",title:"Dr.",name:"Dan",middleName:null,surname:"Close",fullName:"Dan Close",slug:"dan-close"},{id:"194196",title:"Dr.",name:"Michael",middleName:null,surname:"Conway",fullName:"Michael Conway",slug:"michael-conway"},{id:"194197",title:"Dr.",name:"Ashley",middleName:null,surname:"Frank",fullName:"Ashley Frank",slug:"ashley-frank"},{id:"194198",title:"Ms.",name:"Amelia",middleName:null,surname:"Brumbaugh",fullName:"Amelia Brumbaugh",slug:"amelia-brumbaugh"}]},{id:"53039",title:"Going Small: Using Biophysical Screening to Implement Fragment Based Drug Discovery",slug:"going-small-using-biophysical-screening-to-implement-fragment-based-drug-discovery",signatures:"John J. Bowling, William R. Shadrick, Elizabeth C. Griffith and\nRichard E. Lee",authors:[{id:"188526",title:"Mr.",name:"Richard",middleName:null,surname:"Lee",fullName:"Richard Lee",slug:"richard-lee"},{id:"194195",title:"Dr.",name:"John",middleName:null,surname:"Bowling",fullName:"John Bowling",slug:"john-bowling"},{id:"199006",title:"Dr.",name:"Will",middleName:null,surname:"Shadrick",fullName:"Will Shadrick",slug:"will-shadrick"},{id:"199007",title:"Dr.",name:"Elizabeth",middleName:null,surname:"Griffith",fullName:"Elizabeth Griffith",slug:"elizabeth-griffith"}]},{id:"52373",title:"Chemical Similarity Networks for Drug Discovery",slug:"chemical-similarity-networks-for-drug-discovery",signatures:"Yu-Chen Lo and Jorge Z. Torres",authors:[{id:"186645",title:"Dr.",name:"Jorge",middleName:null,surname:"Torres",fullName:"Jorge Torres",slug:"jorge-torres"},{id:"186647",title:"Dr.",name:"Yu-Chen",middleName:null,surname:"Lo",fullName:"Yu-Chen Lo",slug:"yu-chen-lo"}]},{id:"52406",title:"Complex High-Content Phenotypic Screening",slug:"complex-high-content-phenotypic-screening",signatures:"Shane R. Horman",authors:[{id:"187260",title:"Dr.",name:"Shane",middleName:null,surname:"Horman",fullName:"Shane Horman",slug:"shane-horman"}]},{id:"52444",title:"Schistosomiasis: Setting Routes for Drug Discovery",slug:"schistosomiasis-setting-routes-for-drug-discovery",signatures:"Naiara Clemente Tavares, Pedro Henrique Nascimento de Aguiar,\nSandra Grossi Gava, Guilherme Oliveira and Marina Moraes Mourão",authors:[{id:"176676",title:"Dr.",name:"Marina",middleName:null,surname:"Moraes Mourao",fullName:"Marina Moraes Mourao",slug:"marina-moraes-mourao"},{id:"186463",title:"Dr.",name:"Pedro Henrique Nascimento De",middleName:null,surname:"Aguiar",fullName:"Pedro Henrique Nascimento De Aguiar",slug:"pedro-henrique-nascimento-de-aguiar"},{id:"187409",title:"Ph.D.",name:"Sandra",middleName:"Grossi",surname:"Gava",fullName:"Sandra Gava",slug:"sandra-gava"},{id:"187410",title:"Dr.",name:"Naiara Cristina",middleName:null,surname:"Clemente Dos Santos Tavares De Paula",fullName:"Naiara Cristina Clemente Dos Santos Tavares De Paula",slug:"naiara-cristina-clemente-dos-santos-tavares-de-paula"},{id:"187411",title:"Dr.",name:"Guilherme",middleName:null,surname:"Correa Oliveira",fullName:"Guilherme Correa Oliveira",slug:"guilherme-correa-oliveira"}]},{id:"52964",title:"QbD Implementation in Biotechnological Product Development Studies",slug:"qbd-implementation-in-biotechnological-product-development-studies",signatures:"Buket Aksu, Ali Demir Sezer, Gizem Yeğen and Lale Kusçu",authors:[{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",fullName:"Ali Demir Sezer",slug:"ali-demir-sezer"},{id:"195618",title:"Dr.",name:"Buket",middleName:null,surname:"Aksu",fullName:"Buket Aksu",slug:"buket-aksu"},{id:"195619",title:"MSc.",name:"Gizem",middleName:null,surname:"Yeğen",fullName:"Gizem Yeğen",slug:"gizem-yegen"},{id:"195620",title:"MSc.",name:"Lale",middleName:null,surname:"Kuşçu",fullName:"Lale Kuşçu",slug:"lale-kuscu"}]},{id:"53146",title:"Job and Career Opportunities in the Pharmaceutical Sector",slug:"job-and-career-opportunities-in-the-pharmaceutical-sector",signatures:"Josse R. Thomas, Chris van Schravendijk, Lucia Smit and Luciano\nSaso",authors:[{id:"187323",title:"Prof.",name:"Luciano",middleName:null,surname:"Saso",fullName:"Luciano Saso",slug:"luciano-saso"}]}]}]},onlineFirst:{chapter:{type:"chapter",id:"62883",title:"Adenoviral Vector-Based Vaccines and Gene Therapies: Current Status and Future Prospects",doi:"10.5772/intechopen.79697",slug:"adenoviral-vector-based-vaccines-and-gene-therapies-current-status-and-future-prospects",body:'
Adenoviruses (Ads) are non-enveloped, icosahedral DNA viruses with virion size ranges between 70 and 90 nm [1]. They belong to a diverse family (>50 serotypes) of DNA viruses called adenoviridae. Adenovirus was first isolated from human adenoid tissues in 1953 by Rowe and his colleagues [2]. Adenoviruses usually cause non-symptomatic respiratory tract infections in both human and animals but can be life-threatening to immunocompromised individuals. Certain human adenovirus serotypes are ubiquitous in children, and most adults carry neutralizing antibodies to adenoviruses [3]. Nonetheless, since their initial use in gene therapy, they have gained wide recognition as a vaccine antigen delivery vehicle and have proven to be safe and efficient vaccine vectors for eliciting protective immune responses against transgene antigens in many animal and human studies. Recently, adenovirus vectors have been employed to attack cancer cells in cancer therapy [4]. In this chapter, we introduce different adenoviruses and their biology and potential for use in gene delivery, vaccine, and therapeutics in several human diseases. In addition, we will discuss their limitations and future prospects.
Adenoviruses contain a 26–45 kb size double-stranded DNA genome, inside their icosahedral virion [1]. The DNA genome of adenoviruses contains two inverted terminal repeats with 100–140 bp flanks on both the ends. Due to its small genome size, adenoviruses employ several strategies to maximally utilize its genome. For example, they encode proteins from both DNA strands, employ alternate-splicing, and use different poly A modifications of its mRNA. Adenoviral genes can be divided into five early and five late genes. Once internalized into target cells, the adenoviruses express the early genes E1A, E1B, E2, E3, and E4, which modulate host gene expression required for adenovirus protein synthesis and replication. The late transcriptional units include L1–L5 and are required in the assembly, release, and lysis of host cells [1, 5, 6] (Figure 1).
Adenovirus structure and genome organization. (A) Graphical representation of adenovirus structure and various proteins. (B) Adenovirus genome organization showing various early (E) and late (L) transcripts and proteins encoded by each transcript. Regions indicated by red with (*) are deleted in various adenoviral vectors. E1 and E3 regions were deleted in first generation and E1, E2, E3, and/or E4 were deleted in second-generation adenoviral vectors. Most recent adenoviral vectors called helper-dependent adenoviral vectors only contain ITRs and packaging signals. Figure is adapted from Ref. [
Structurally, adenovirus consists of a core of capsid and genome. The viral capsid consists of structural proteins hexon, penton, fiber, IIIa, VIII, and IX. Hexons are major surface structural proteins consisting of 270 trimers, which are arranged as 12 pentamers of pentons at the top of 12 icosahedral vertices. Hexons also contain several hypervariable regions and are the main targets of neutralizing antibodies. In adenoviral vectors, these sites can be engineered to carry vaccine antigen. Each icosahedral vertex gives rise to protruding fibers consisting of 12 trimers. Both penton and fiber proteins serve as ligands for host cell receptors and help in viral entry. The IIIa proteins are located in the inner surface of the capsid and help in the assembly and stabilization of vertex regions and also in the assembly of packaged viral genome. The VI proteins link the outer capsid shell to the inner icosahedral shell. The VIII proteins help in bonding hexons together and are critical for the stability of the viral capsid. The proteins V, VII, and X are associated with the DNA genome and make up the virion core. Terminal protein binds to each end of the DNA genome [6, 7, 8] (Figure 1).
The early gene first transcribes E1A protein, an essential protein for viral replication. The E1A protein activates the transcription of other viral genes responsible for viral DNA synthesis. In host cells, E1A stimulates apoptosis by both p53-dependent and -independent pathways [9]. In contrast, the E1B protein inhibits apoptosis by binding to several host cell proteins such as p53, Bak, and BAX proteins [8]. In non-replicating adenoviral vectors, the E1 gene is deleted to render them replication-defective so that it can infect the host cells but cannot multiply. However, for production of non-replicating adenoviral vectors, E1 transfected cells such as HEK293 and PER.C6 are used to allow production of replication-defective adenoviral vector [9].
Adenoviruses are grouped under the family Adenoviridae, which is divided into five genera: Mastadenovirus, Aviadenovirus, Siadenovirus, Atadenovirus, and Ichtadenovirus. Human adenoviruses, along with many animal adenoviruses (monkeys, cattle, sheep, swine, dogs), belong to the genus Mastadenovirus. Human adenoviruses (HAd) are classified into seven subgroups: A–G and further in to 67 serotypes based on serological properties. The classification of serotypes into subgroups is based on their similarities in genome organization and DNA sequences, host tropism, carcinogenic potential in rodents, and growth properties in cell cultures. Adenoviral serotyping is based on viral surface antigen neutralizing antibodies and by phylogenetic distance (>10%) in the viral genes that encode viral protease, the protein pVIII, the hexon protein, and the DNA polymerase [10, 11, 12].
The genus Aviadenovirus contains bird adenoviruses, while other genera Siadenovirus, Atadenovirus, and Ichtadenovirus contain other adenoviruses of mammals, birds, reptiles, and fishes [13, 14, 15]. The adenoviruses isolated from sheep, cattle, deer, possum, and some birds differ from the adenoviruses of the genus Mastadenovirus and are classified under the genus Atadenovirus [6, 16, 17]. The adenoviruses of the genus Mastadenovirus have high A + T (adenine and thymidine)-rich genomes and lack the early region 1 (E1) transcriptional unit. Adenoviruses isolated from many invertebrates are classified under the new genus Siadenovirus. Human and animal adenovirus infections are very common, and the majority of the population of host species contain neutralizing antibodies against the most prevalent serotypes of adenoviruses. Both human and non-human adenoviruses have been studied extensively and are the basis of adenoviral vector-based vaccine and gene therapies [18, 19]. In humans, infection by non-human adenovirus serotypes is not common. However, due to broad tissue tropism and structural and genomic similarity with human adenoviruses, non-human adenoviruses can infect various human tissue types. These properties of adenoviruses encouraged researchers to use non-human adenoviruses as gene or vaccine antigen delivery vectors to mitigate the pre-existing neutralizing immunity that commonly exists against human adenoviral vectors. Several non-human adenoviruses such as bovine Ad serotype 3 (BAd3); canine Ad serotype 2 (CAd2); chimpanzee Ad serotypes 1, 2, 3, 5, 6, 7 and 68 (ChAd1, ChAd2, ChAd3, ChAd5, ChAd6, ChAd7, ChAd68); ovine Ad serotype 7 (OAd7); porcine Ad serotype 3 and 5 (PAd3, PAd5); and fowl Ad serotypes 1, 8, 9, and 10 (FAd1, FAd8, FAd9, FAd10) are currently being tested as vaccine or gene delivery vectors [18, 20, 21, 22]. Extensive research in the molecular biology of both human and non-human Ads has helped in better understanding of the adenoviruses and designing of adenoviral vectors.
Initially, a host detects the invading virus by sensing unique pathogen-associated molecular patterns (PAMPs) present on the pathogen through pattern recognition receptors (PRRs). Once activated, these PRRs transmit signal to express type I interferons (IFNs) and proinflammatory cytokines which inhibit viral replication and recruit various innate immune cells to the site of infection [23, 24, 25, 26, 27]. These initial events ensure the efficient activation and presentation of viral antigens by the antigen-presenting cells to T cells and result in the induction of adaptive immune responses. In the following sections, we will discuss innate and adaptive immune responses to Adenoviruses in detail.
Adenoviruses are known to induce robust innate immune responses in their hosts. The adenovirus binds to its receptor(s) (such as Coxsackie adenovirus receptor or CAR, integrin αvβ5 heparin sulfate proteoglycans, CD46, sialic acid, etc.) on host cells and gains entry into the cytoplasm [28, 29, 30, 31, 32]. However, phagocytic antigen-presenting cells such as macrophages and dendritic cells can also take up virus particles through scavenger receptors [33]. Inside a host cell, the virus can be recognized by various intracellular molecular sensors such as Toll-like receptors (TLRs), RIG-I like receptors (RLRs), nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), cytosolic DNA sensors, and effector molecules [34, 35, 36].
Cytokines such as IL-8 and TNF-α enhance the entry of human adenovirus type C by increasing the availability of CAR and integrin receptors, which facilitate the adenovirus to enter through clathrin-mediated dynamin-dependent endocytosis [27, 33, 37, 38]. The type B human adenoviruses use CD46 or desmoglein-2 and enter host cells through macropinocytosis [39, 40]; this also results in the suppression of IFN-γ-induced production of proinflammatory cytokine IL-12 [41].
One of the major drawbacks of the use of adenovirus in gene therapy is the induction of undesired innate immune responses. In liver and spleen, the resident macrophages can sense and trap blood-borne adenovirus and induce inflammatory response mediators [42, 43]. Adenovirus also activates TLR2-dependent expression of chemokines such as MCP-1 and RANTES. In mice, TLR2 deficiency resulted in reduced NF-κB activation and humoral responses to HAd vector antigens and transgene-encoded antigens [42]. However, TLR2 deficiency did not result in complete inhibition of acute and adaptive responses to HAd, suggesting the involvement of an additional pathway [44]. The cellular β3 integrins were recently reported to interact with arginine-glycine-aspartic acid (RGD) motifs of viral homo-pentameric penton base protein during viral entry, which results in the processing of inactive IL1α into active cytokine in a MyD88-, TRIF-, and TRAF6-independent signaling pathway [43]. The IL1α plays a major role in adenovirus-induced inflammatory responses. The IL1R-deficient mice or wild-type mice treated with anti-IL-1 antibodies demonstrated reduced inflammatory responses as well as hepatotoxicity in adenovirus infection [45]. Further, the interaction between the adenoviral RGD motif and host β3 integrin mediates chemokine secretion, leukocyte infiltration, as well as corneal inflammation in human adenovirus serotype 37 infections [46].
TLR9 also plays a significant role in innate immunity against adenoviruses. Macrophages have been reported to sense adenovirus, helper-dependent adenoviral vector and recombinant E1- and E3-deleted adenovirus through TLR9 [47, 48]. The TLR9-deficient mice show reduced proinflammatory responses and IFN-α production upon adenoviral vector delivery. In a mouse model pf keratitis, adenovirus induced TLR9-dependent IL6 production and monocyte infiltration of the cornea; however, chemokine secretion and keratitis development were TLR9-independent [49, 50]. Another study showed that recombinant adenovirus-induced type I IFN production in plasmacytoid dendritic cells (pDCs) is TLR9-MyD88-dependent but in myeloid DCs (mDCs) and macrophages, it is TLR9-independent [48].
The viral DNA also plays a critical role in the induction of innate immune responses as empty adenoviral particles are found to be poor inducers of innate responses [51]. The presence of double-stranded RNA with 5′-triphosphate groups in the cytoplasm of target cells is sensed by cytosolic PRR such as RIG-I, and viral DNA and RNA are recognized by intracellular PRRs such as TLR3, 7, and 8 present on the endosomal membrane [48, 52, 53, 54, 55]. The double-stranded DNA is sensed by TLR9 in the intracellular environment and also by DNA-dependent activator of IRFs (DAI), DNA-dependent protein kinase (DNA-PK), IFN-γ-inducible protein 16 (IFI16), DEAD (Asp-Glu-Ala-Asp) box polypeptide 41 (DDX41), and by cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) [34, 35, 56, 57]. Other cytosolic viral DNA sensors are NOD-like receptors (NLRs), which consist of a central nucleotide-binding domain responsible for ATP-dependent self-oligomerization, a C-terminal leucine-rich repeat (LRR) domain that senses the presence of a ligand, and a variable N-terminal interaction domain that mediates protein-protein interactions. The NLR activation leads to the formation of inflammasomes with the help of microtubules [58]. The human adenovirus activates the formation of two types of inflammasomes in myeloid cells: absent in melanoma-2 (AIM2) and NLR-pyrin domain (PYD)-containing protein (NALP3). The activation of inflammasomes induces inflammatory responses via NF-κB signaling, converts pro-IL1β and pro-IL18 into IL1β and IL18, respectively, and can lead to DNA fragmentation, membrane pore formation, and eventually cell death by pyroptosis [59].
The early adenoviral proteins E1, E3, and E4 interfere with the innate immune signaling and help in evading host immune responses. The E1A protein allows hijacking of cell cycle, inducing apoptosis, evading immuning, inducing tumorigenesis, and expressing viral genes [60, 61]. The E1A has been reported to block type 1 IFN-inducible gene expression [62, 63, 64], type 2 IFN-γ-dependent HLA class II expression, and IFN-β expression in response to double-stranded RNA due to inhibition of transcription complex formation [62]. Furthermore, E1A inhibits IFN-alpha-stimulated transcription factor 3 (ISGF3), IFN-stimulated genes (ISGs) [65, 66], and immunoproteasomes, resulting in reduced antigen presentation to T cells [67]. In addition, the early adenoviral proteins E1B-19K and E1B-55K antagonize p53-mediated apoptosis [68, 69], and E1B-55K interferes with the induction of IFN-inducible genes [70, 71]. The E1B-55K and E4 proteins induce proteasome-mediated degradation of defense factor death domain-associated protein (Daxx) resulting in the removal of viral transcription blocking allowing viral gene expression [72, 73]. E1B-55K and E4 protein complex also result in inhibition of antiviral innate immune responses [74, 75, 76, 77]. The E3 protein has several immune modulatory functions. It blocks the surface transport of MHC-class I molecule and also reduces NK cell receptors on host cells, masking infected cells from detection by immune cells [78]. Furthermore, the E3 protein also inhibits apoptosis of adenovirus-infected cells by downregulation of death receptors [79].
The induction of innate immune responses is critical in adenoviral vector-based strategies. On the one hand, the gene transfer vector should have minimal activation of innate immune signaling to allow efficient gene delivery without immune activation. On the other hand, adenoviral vector-based vaccine antigen delivery could benefit from adenovirus’s intrinsic property of innate immune activation that results in efficient activation of transgene-specific adaptive immune responses. Therefore, careful engineering of adenoviral vectors can serve the purpose of both gene and vaccine antigen delivery.
The adaptive immune responses to adenoviruses are directed against both early and late viral proteins. They include both neutralizing antibodies and T cells against viral surface antigens such as hexon, penton, and fiber proteins. However, these adaptive immune responses against adenoviral antigens also present major obstacles in adenoviral vector development as gene delivery, and vaccine antigen carriers limit the number of administrations that can be done and reduce the efficiency of transgene expression. Both humoral and cellular immune responses are discussed in detail in the following sections.
The surface antigens of adenovirus, penton, hexon, and fiber proteins are involved in host cell receptor interaction and can be neutralized by antibodies. The impact of neutralizing antibodies (nAbs) on adenoviral gene and antigen delivery has been studied extensively [80, 81, 82]. The passive transfer of serum from Ad immune mice or purified nAbs against adenoviruses decreases the vector transgene expression and induction of transgene-specific cellular and humoral responses. Depletion of antibodies against fiber, penton, and hexon by affinity chromatography has been shown to significantly enhance the transgene expression and induced immune responses. Furthermore, hexon-specific antibodies seem to play a relatively dominant role
In humans, Ad vector-specific CD4+ Th1 cells have been detected, but the frequencies of these cells decrease with age [87]. The CD8+ T cell responses to different structural proteins have also been detected in animals in response to adenovirus infection or adenovector administration [19, 80, 88]. Due to extensive homology between different adenoviral structural antigens, both human and mouse-derived CD4+ and CD8+ T cells cross react with human and simian Ad serotypes [20, 89, 90]. Similar to nAb, pre-existing Ad-specific T cells can also reduce Ad vector transgene expression and immunity. Furthermore, Ad-specific T cells have been detected in 80–100% of human subjects in various studies, which make them even more important in Ad vector development [89]. The human studies examining both nAbs and T cells demonstrated a higher proportion of individuals possessing T cell responses compared to nAbs against Ad. The pre-existing Ad-specific T cells have greater consequences for Ad vaccine vector development due to their cross-reactive nature, higher distribution in the human population, and their multifunctional nature [22]. Finally, human Ad vector has also recently been reported to induce cross-reactive hepatitis C virus-specific humoral and cellular immune responses [91]. Widespread use of adenoviral vectors in humans will induce such cross-reactive immune responses at high levels, which might be beneficial or detrimental in the development of natural immunity against HCV and affect the immunopathology and disease progression of HCV infection.
Adenoviruses are engineered to make them safe and efficient for human use as vaccine and gene and cancer therapy vectors by deleting certain genome sequences. Initially, human adenoviruses, especially adenovirus 5 (HAd5), were developed as gene delivery vectors. Since the first generation of adenoviral vectors, based on E1 deletion, a number of different strategies have been employed to further improve the gene-carrying capacity and safety by deleting more genes. These strategies can be summarized under following three categories.
First-generation adenoviral vectors were prepared by deleting early gene E1 to render them replication-defective and create space for a transgene sequence of up to 4.5 kb [92]. Since these vectors lack the E1 region essential for their replication, cell lines such as human embryonic kidney cells (HEK293) were engineered to incorporate viral E1 region [93]. The E1 region in the HEK293 cell line provides trans-complementation and allows the replication of the adenoviral vector [94, 95, 96, 97]. These adenoviral vectors carry native tissue transduction capability and efficiently express the transgene in target host cells. However, there are possibilities of spontaneous homologous recombination between vector and E1 regions during amplification inside HEK293 cells, which might enable replication competent adenoviral (RCA) vectors to emerge [98]. To mitigate this problem, another cell line, human embryonic retinoblasts (PERC.6), was made by inserting an expression cassette for the adenoviral E1 region with its own promoter (ubiquitous phosphoglycokinase, PGK) [99]. This eliminates the adenoviral vector homologous regions from the E1 promoter and therefore the chances of recombination [100]. Adenoviral E3 region proteins are known to inhibit immunological pathways [101]. Therefore, the adenoviral E3 region was removed either partially or completely without affecting
Methods of preparation of different types of adenoviral vectors. (A) First generation. The target gene is cloned into a shuttle vector containing 5′-ITR, a packaging signal, and the sequence for homologous recombination. This shuttle vector and an adenoviral backbone vector are transfected into HEK-293 cells, and adenoviral vector is created through homologous recombination between the two vectors. (B) First or second generation. The target gene is cloned into a shuttle vector that contains 5′-ITR, a packaging signal, and an LoxP site(s). This shuttle vector and a LoxP-containing adenoviral backbone vector are joined together through Cre recombinase-mediated recombination either
Second-generation adenoviral vectors possess deletions in E2 or E4 regions that encode for proteins required for replication in target cells [106, 107, 108]. These deleted proteins were complemented in trans by cell lines (such as HEK293) to allow for vector propagation. These second-generation vectors provided additional space for larger cargo sequences (10.5 kb) with up to four independent expression cassettes and eliminated the possibility of generating replication-competent adenoviruses during amplification. This deletion of early viral genes impacts the amplification of viral vector in cell culture and results in lower yields due to inefficient complementation by the producer cell lines [107, 109]. These vectors also have been reported to have lower transgene expression. Immunogenicity and cellular toxicity are still a major concern in the second-generation adenoviral vectors [110] (Figure 2A–C).
Third-generation adenoviral vectors are also called “high capacity adenoviral vectors” (HCAds) because they can accept cargo sequences up to 36 Kb [111, 112, 113]. The HCAds were generated by deleting all viral sequences except the ITRs and the packaging signal [114]. For replication of third-generation adenovirus vectors in cell culture, instead of the complementation by the viral genes encoded by host cells, an additional adenoviral helper virus is provided. Therefore, the third-generation adenoviral vectors are also called helper-dependent or “gutless” adenoviral vectors [115, 116, 117]. The helper adenovirus is generated like a first-generation adenoviral vector and includes packaging signal flanking loxP sites. The vector is produced in HEK293 cells that constitutively express Cre recombinase by simultaneously transducing helper virus and the HCAd genome. This allows the synthesis of adenoviral proteins by the helper virus and enables assembly of viral capsids, resulting in the packaging of HCAd genome only. The helper virus genome-packaging signal is excised by Cre-mediated recombination of the loxP sites, thus preventing helper virus genomes from assembling into viral particles. In some production systems, other recombinases like
Since their first use in gene therapy, adenoviral vectors have progressed significantly and are currently being tested clinically in several gene therapy, vaccine vector, and anticancer studies.
Adenoviruses have a unique ability to infect a broad range of cell types. Therefore, adenovirus-based vectors can be used to transduce and deliver transgenes to different cell types including both replicating and quiescent cell populations. This property of adenoviral vectors is extremely important in gene therapy and puts adenoviral vectors on top of viral vectors for gene delivery. Furthermore, adenovirus vectors do not integrate into host genomes but stay as episomal DNA in the nucleus of host cells. Modern adenoviral vectors can take multiple gene cassettes, up to 36 kb of foreign DNA, which make them suitable for delivering virtually any size of gene. In 1992, for the first time, a first-generation adenoviral vector was used to deliver and express alpha-1 antitrypsin (A1AT) in hepatocytes of a patient who had alpha-1 antitrypsin deficiency [124]. In another study, an E1–E3 deleted HAd5 adenoviral vector was used to deliver an A1AT gene to lung tissues [125]. Later, using adenoviral vectors, a number of attempts were made to deliver dysfunctional or deficient genes, which were responsible for several human genetic diseases and conditions. Cystic fibrosis is one such human genetic disease, in which the gene CFTR (cystic fibrosis transmembrane conductance regulator) becomes dysfunctional due to mutation. Adenoviral vector was used to deliver CFTR genes to lung tissues [126]. In another study, the adenoviral vector was used to deliver the gene for ornithine transcarbamylase, which is required in the urea cycle and is responsible for ornithine-transcarbamylase deficiency [127, 128]. These studies faced several challenges including humoral and cellular immunity to adenoviral vectors upon repeated administration of vector, cellular cytotoxicity, and oncogenesis [129]. These trials raised serious safety concerns for using adenoviral vectors in gene therapy and resulted in a sharp decline in their use. The reasons for these problems were studied extensively and addressed by constructing new adenoviral vectors. The adenoviral immunogenicity and cytotoxicity were suspected to be due to low-level expression of several viral proteins. The newer generations of adenoviral vectors had these adenoviral genes removed, and hence the vector immunogenicity and toxicity were significantly reduced. The new generations of adenoviral vectors have raised new hope in adenoviral vector-based gene delivery. Currently, a number of gene therapy clinical trials are ongoing with adenoviral vectors (Table 1). The previous generation of adenoviral vectors is still in use for vaccine antigen delivery due to their inherent capability of inducing robust humoral and cellular immune responses.
S. no. | Adenoviral vector (biologic) | Modification | Transgene | Target/condition | Phase | ClinicalTrials identifier |
---|---|---|---|---|---|---|
1 | HAd5-CB-CFTR | E1 deleted | Cystic fibrosis transmembrane conductance regulator (CFTR) gene | Cystic fibrosis | I | NCT00004779 |
2 | HAd5-hAQP1 | E1 deleted | Human aquaporin-1 (hAQP1) | Parotid salivary dysfunction | I | NCT00372320 |
3 | HAd5-PDGF-B | E1 deleted | Platelet-derived growth factor B (PDGF-B) | Varicose ulcer | I | NCT00000431 |
4 | HAd5-PEDF (AdGVPEDF.11D) | E1, E3 and E4 deleted | Pigment epithelium-derived factor (PEDF) protein | Macular degeneration | I | NCT00109499 |
5 | HAd5-VEGF | E1–E3-deleted | Vascular endothelial growth factor D (VEGF-D) gene | Angina pectoris/myocardial infarction | I | NCT01002430 |
Gene therapy: adenoviral vectors in clinical trial.
As described earlier, adenoviruses activate several innate immune signaling pathways that result in the secretion of a number of proinflammatory cytokines. These proinflammatory cytokines pave the way for effective immune cell stimulation and result in the induction of robust adaptive humoral and cellular immune responses. To resolve infections with intracellular pathogens such as viruses, CD8+ cytotoxic T lymphocyte (CTL) responses are critical. Transgene antigens carried by adenoviral vectors are presented to T cells via MHC class I molecules, and therefore, they induce efficient and robust CTL responses. The CTLs efficiently recognize and kill virus-infected cells, intracellular pathogens, and cancerous cells. These properties make adenoviral vectors promising as vaccine vectors. A number of human clinical trials have been conducted for adenoviral vector-based vaccines against different infectious diseases including Ebola virus, Zika virus, influenza viruses, HIV,
An HAd5 vector-based HIV vaccine containing clade B sequences of
In 2009, another famous HIV vaccine clinical trial (HVTN phase II) was started [143]. It utilized a heterologous prime-boost strategy, in which vaccinees were first primed with a DNA-based vaccine expressing HIV proteins (envA, envB, envC, gagB, polB, nefB) followed by a booster Ad5 vector vaccine having matching HIV antigens as transgenes. This trial too met with the same fate as STEP, as the vaccine failed to reduce the HIV acquisition rate or attenuate the disease in infected subjects. It was terminated in 2013 prior to completion. However, this study and several other studies provided evidence of superior response rates, induction of broader T cell immune responses with well-accepted tolerance, by heterologous prime-boost vectors compared to homologous vaccination [144]. This started a new vaccination regimen involving priming with one type of adenoviral vector and boosting with another adenoviral vector derived from novel serotypes such as HAd26 and HAd35. This allowed for repeated vaccination and also vaccination in individuals with pre-existing vector immunity [145, 146, 147, 148, 149]. Currently, a number of non-human adenoviral vectors such as chimpanzee and bovine are also being utilized to avoid pre-existing vector-specific immunity [18, 21, 150, 151, 152].
Due to the emergence of life-threatening infectious diseases such as Ebola and Zika viruses, an immediate need for vaccines for these pathogens was recognized. These urgent needs attracted researchers toward viral vector platform-based vaccines, especially extensively studied and improved vector technology, and adenoviral vectors became the focus of several vaccines against these infectious diseases [21, 130]. Adenoviral vector-based vaccines are easy to design and to produce on a mass scale, which is of paramount significance for clinical use. Therefore, three adenoviral vector-based vaccines encoding Ebola virus glycoprotein, ChAd3-ZEBOV1 from GlaxoSmithKline [153], Ad26-ZEBOV/MVA-BN-Filo2 from Johnson & Johnson [154], and HAd5 from the Chinese federal agency [155] were quickly generated and tested in macaques. Each of them proved to be well tolerated, immunogenic, and protective in macaques. All these vaccines were also well tolerated, safe, and immunogenic in phase I clinical trials, and the ChAd3- and ChAd26/MVA-based vaccines progressed further into phase II and phase III efficacy trials [156, 157]. The Chinese Ad5-based Ebola vaccine showed less efficacy in phase I clinical trial in individuals with pre-existing adenoviral immunity [158]. Beside these, a chimpanzee adenoviral vector ChAd63 prime/MVA boost-based malaria vaccine, which contains
Despite initial setbacks, adenoviral vector-based vaccines are still very attractive and promising vaccine platforms. Currently, several adenoviral vector-based vaccines are in different stages of clinical development (Table 2).
S. no. | Adenoviral vector (biologic) | Modification | Transgene | Target/condition | Phase | ClinicalTrials identifier |
---|---|---|---|---|---|---|
1 | HAd5-EBOV | E1-deleted | Glycoprotein | Ebola virus disease | II | NCT02575456 |
2 | ChAd3-EBO-Z | E1-deleted | Glycoprotein | Ebola virus disease | I/II | NCT02289027 |
3 | ChAd3-EBO-Z/MVA-EBOV-Z-BN-Filo Prime/Boost | E1-deleted | Glycoprotein/envelope filovirus | Ebola virus disease | I | NCT02267109 |
4 | Ad26-EBOV-Z/MVA-BN-Filo Prime/boost | E1 and E3 deleted | Glycoprotein | Ebola virus disease | I | NCT02891980 |
5 | Ad26-EBOV-Z/MVA-BN-Filo Prime/boost | E1 and E3 deleted | Glycoprotein | Ebola virus disease | III | NCT02661464 |
6 | HAd6-Nsmut/VhAd3NSmut or CHAd3NSmut/HAd6NSmut Prime/boost | E1-deleted | Non-structural protein | Hepatitis C | I | NCT01070407 |
7 | AdCh3NSmut/Ad6NSmut | E1-deleted | Non-structural protein | Hepatitis C | I | NCT01094873 |
8 | HAd5-HA (VXA-1.1) | E1-deleted | Hemagglutinin and double-stranded RNA as an adjuvant | Influenza H1N1 | II | NCT02918006 |
9 | HAd5-HA | E1/E3-deleted | Hemagglutinin | Influenza H5N1 | I | NCT00755703 |
10 | HAd4-HA5-Vtn HA | E3-partial deletion | Hemagglutinin | Influenza H5N1 | I | NCT01006798 |
11 | HAd35-CSP/HAd26-CSP Vectors Prime/boost | E1 and E3 deleted | Circumsporozoite (CSP) antigen | Malaria | I/II | NCT01397227 |
12 | HAd5 (NMRC-M3V-Ad-PfCA) | E1, E4 deleted, E3 partially deleted | Circumsporozoite (CSP) antigen, apical membrane antigen 1 (AMA1) | Malaria | I/II | NCT00392015 |
13 | ChAd63-ME-TRAP/MVA-ME-TRAP poxvirus Prime/boost | E1-deleted | ME-TRAP antigen (pre-erythrocytic thrombospondin-related adhesion protein) | Malaria | I | NCT01373879 |
14 | HAd35-TB Antigens/MVA85A Prime/boost (AERAS-402, BCG) | E1-deleted, HAd5 E4 orf6 replaced | TB antigens: Ag85A, Ag85B, and TB10.4 | Tuberculosis | I | NCT01683773 |
15 | HAd35-TB Antigens (AERAS-402) | E1-deleted, HAd5 E4 orf6 replaced | TB antigens: Ag85A, Ag85B, and TB10.4 | Tuberculosis | II | NCT02414828 |
16 | Four HAd5 vectors for four HIVAntigens (VRC-HIVADV014-00-VP/VRC-HIVADV014-00-VP) | E1, E4 and partial E3 deleted | HIV antigens gp140(A), gp140(B)dv12, gp140(C) and GagPol(B) | HIV infections | I | NCT01549509, NCT00119873, NCT00091416, NCT00709605, NCT00102089 |
17 | Plasmid DNA expressing Gag, Plo and Nef +Four HAd5 vectors for four HIVAntigens (VRC-HIVDNA016-00-VP/VRC-HIVADV014-00-VP), DNA + HAd5/HAd5 Prime/boost | E1, E4 and partial E3 deleted | HIV antigens gp140(A), gp140(B)dv12, gp140(C) and GagPol(B) | HIV infections | I/II | NCT00123968, NCT00125970 |
18 | Plasmid DNA vaccine/HAd5-HIV-1 (VRC-HIVDNA016-00-VP/VRC-HIVADV014-00-VP) prime/boost | E1, E4 and partial E3 deleted | HIV antigens gp140(A), gp140(B)dv12, gp140(C) and GagPol(B) | HIV infections | II | NCT00865566 |
19 | DNA Vaccine/HAd35/HAd5 (VRC-HIVDNA044-00-VP/VRC-HIVADV027-00-VP/VRC-HIVADV038-00-VP) HAd35/HAd5 prime/boost or DNA/HAd5 prime/boost or DNA/HAd35 prime/boost | E1-deleted | Gag, pol and Nef antigens | HIV infections | I | NCT00801697 |
20 | HAd26 (HAd26.ENVA.01) | E1 and E3 deleted | Env gp140 | HIV infections | I | NCT00618605, NCT01103687 |
21 | HAd4-mgag, HAd4-EnvC150 alone or combination | Replication competent | mosaic HIV Gag antigen, HIV clade C Env protein (gp150 1086.C) | HIV infections | I | NCT02771730, NCT01989533 |
22 | rcAd26.MOS1.HIV-Env 1 | E3 or E3/E4 deleted | HIV-1 Mos1Env | HIV infections | I | NCT02366013 |
23 | Ad26.Mos.HIV (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol)/MVA-Mosaic prime/boost | E3 or E3/E4 deleted | Hiv gag, pol and Env | HIV infections | I/II | NCT02919306 |
Vaccine delivery: adenoviral vectors in clinical trials.
Several DNA viruses such as reo, measles, herpes simplex, Newcastle disease, and vaccinia have been tested in clinical trials for anticancer immunotherapy. The mechanism of anticancer activity of these viruses is multipronged. One mechanism involves selective infection and replication in tumor cells where expression of viral antigens or oncogenes inside the cancer cell changes the tumor microenvironment by inducing proinflammatory cytokines. These subsequently attract immune cells to the tumors eventually resulting in lysis of the tumor cells. Another mechanism uses vectors to deliver gene(s) whose expression results in the apoptosis of cancer cells or lysis of cancer cells due to replication by replication-competent viral vectors [160, 161]. Adenoviral vector technologies have progressed to the clinical stage for various cancers and also have been approved in some countries for use in human [162, 163, 164].
Various anticancer approaches have been tested using adenoviral vectors. One of these approaches depends on the induction of immune responses by delivering specific tumor-associated antigen as a vaccine, which activates immune cells against the tumor [165, 166, 167, 168]. Due to immunogenic properties of adenoviral proteins such as capsid, adenoviral vectors induce robust CTL responses, which eventually kill the tumor cells expressing these tumor antigens. However, this vaccination strategy has shown limited success in cancer.
Another approach uses conditional replicative adenoviral vector (CRAd) to preferentially replicate inside a tumor cell and eventually lyse it through a lytic replication [162]. This strategy takes advantage of the conducive nature of cancer cells toward adenoviruses. Adenoviral vectors have been modified to efficiently carry out oncolytic replication in cancer cells while limiting their replication in healthy cells [9, 169]. An adenoviral vector with a partial E1B gene deficiency called ONYX-015 became the first ever adenoviral vector to enter clinical trial in 1996 [169]. The ONYX-015 is unable to replicate in healthy cells expressing p53 but replicates in p53-deficient tumor cells and results in the lysis of the cell, taking advantage of the cancer cell environment that supports vector replication [9]. The ONYX-015 has been proven to be safe and well tolerated in patients with various advanced cancers and is reported to be even more effective when administered in combination with standard chemotherapy [169, 170]. A similar adenoviral vector named Oncorine or H101, developed by Shanghai Sunway Biotech, was approved by the Chinese Food and Drug Administration agency for the treatment of head and neck cancer [171, 172]. To further enhance the efficacy, potency, and specificity of the oncolytic adenoviral vectors, a new generation of adenoviral vectors is being tested. These new adenoviral vector systems carry a suicide gene like HSV thymidine kinase or a cytotoxic prodrug under the control of tumor gene/antigen promotor like prostate antigen promotor [173, 174, 175].
In some studies, replication-deficient or replication-competent adenoviral vectors were used to deliver transgenes, which express a tumor suppressor protein or cytotoxic/suicide protein that induces cell cycle arrest or a death cascade [176, 177]. More than 50% of cancers have a mutation in tumor suppressor gene p53. Advexin is a replication-deficient adenoviral vector that expresses p53 through a CMV promotor. It was tested in both preclinical and more than a dozen phase I/II clinical trials and proved to be well tolerated and efficacious against colorectal cancer, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), prostate cancer, breast cancer, ovarian cancer, bladder cancer, glioma, and squamous cell carcinoma of the head and neck [171, 178, 179]. Gendicine, a similar adenovirus vector developed by a Chinese Biotech Company, Shenzhen SiBiono GeneTech, differs only in that its transgene promotor is from Rous Sarcoma Virus. In 2003, Gendicine was approved by the Chinese Food and Drug Administration agency as a first-ever gene therapy product to be used in combination with chemotherapy to treat head and neck squamous cell carcinoma [4, 178, 180]. Since then, Gendicine has been tested in a number of clinical trials against different types of cancers such as HCC, NSCLC, malignant glioma, and epithelial ovarian carcinoma. It is reported to be well tolerated and provide progression-free long-term survival benefits in combination regimens when compared to standard therapies alone [4, 178, 180, 181]. Therefore, adenoviral vectors have been clinically successful in anticancer therapy and have shown tremendous potential in the treatment of several cancer types [4, 171, 180, 181]. However, there is still scope for further improvements in clinical efficacy and safety (Table 3).
S. no. | Adenoviral vector (biologic) | Modification | Transgene | Target/condition | Phase | ClinicalTrials identifier |
---|---|---|---|---|---|---|
1 | ICOVIR-5 | E2F-E1A Δ24 RGD | — | Solid tumors | I | NCT01864759 |
2 | LOAd703 | 5/3 Δ24 | CD40L & 4-1BBL | Pancreatic cancer | I/IIa | NCT02705196 |
3 | HAd5-yCD/mutTKSR39rep-hIL12 | E1B-55K | Cytosine deaminase (CD)/tyrosine kinase (TK) hIL12 | Prostate cancer | I | NCT02555397 |
4 | ONCOS-102 with cyclophosphamide | 5/3 Δ24 | GM-CSF | Advanced neoplasms | I | NCT01598129 |
5 | VCN-01 with or without abraxane and gemcitabine | DM-1-E2F-E1A Δ24 RGD | Hyaluronidase | Advanced solid tumors | I | NCT02045602 |
6 | VCN-01 with abraxane and gemcitabine | DM-1-E2F-E1A Δ24 RGD | Hyaluronidase | Advanced pancreatic cancer | I | NCT02045589 |
7 | CG0070 | E2F-E1A | Granulocyte macrophage colony-stimulating factor (GM-CSF) | Bladder cancer | III | NCT02365818 |
8 | CG0070 | E2F-E1A | GM-CSF | Bladder cancer | II/III | NCT01438112 |
9 | Colo-Ad1 | Ad11p/Ad3 | — | Colon, non-small cell lung cancer, bladder, renal cancer | I | NCT02053220 |
10 | DNX-2401 with Temozolomide | E1A Δ24 RGD | — | Glioblastoma multiforme | I | NCT01956734 |
11 | DNX-2401 with IFNγ | E1A Δ24 RGD | — | Brain tumors | I | NCT02197169 |
12 | Ad5-yCD/mutTKSR39rep-ADP with intensity-modulated radiation therapy (IMRT) | E1B-55K | CD/TK | Prostate carcinoma | II/III | NCT00583492 |
13 | OBP-301 | hTERT | — | Hepatocellular carcinoma | I/II | NCT02293850 |
Oncolytic therapy: adenoviruses in clinical trial.
Development of adenoviral vectors has come a long way since their first use. Currently, different types of adenoviral vectors are available for different applications. In the beginning, a high prevalence of pre-existing immunity to adenoviral vectors was considered as a serious concern for their use in mass vaccination and gene therapeutic applications. Further, immunogenicity, cellular toxicity, and oncogenesis were also major obstacles in gene therapy applications. Many other concerns, such as the possibility of vectors regaining replication competence, non-specificity, immunodominance of adenoviral antigens over the vaccine transgene antigen(s), immune modulation by viral antigens, heterologous immunity with other pathogens, are still evident in many adenoviral vector-based vaccine and gene therapy approaches [182]. These are discussed in the following sections.
Adenoviruses can infect a diverse range of mammalian cell types. Infection to host cells is mediated by binding of adenoviral fiber protein to host cell surface receptors followed by recruitment of RGD motifs on penton bases to bind the host cell alpha-integrins. Most common human adenoviruses (HAd5 and HAd2) bind to coxsackie adenovirus receptor (CAR) present on many different cell types including epithelial, endothelial, hepatocytes, myoblasts, and heart muscle cells. Some cells such as lymphocytes do not express CAR themselves but harbor CAR-recognizing adenoviruses. Adenovirus from subgroup B such as HAd35 do not bind to CAR but recognize another complement regulatory receptor CD46 present on most nucleated human cells, hematopoietic stem cells, and dendritic cells. Another subgroup B adenovirus HAd3 binds to CD80 and CD86 costimulatory molecules on antigen-presenting cells [8, 166, 183, 184]. Other cellular receptors such as integrin αvβ5, heparin sulfate proteoglycans, and sialic acid have also been reported to aid adenoviral entry to the cells [30, 31, 32, 185].
The impact of pre-existing immunity against adenoviral vectors has been discussed in the previous section under adaptive immunity. To avoid the pre-existing immunity against adenoviral vectors, several strategies are being employed as discussed below.
Several human adenoviruses with low seroprevalence such as HAd2, HAd26, and HAd35 were identified and developed into vectors [186]. The seroprevalence of these rare human adenovirus serotypes is very low, and hence the effect of pre-existing immunity is minimal [81, 187]. HAd26 and HAd35 vectors have been tested in phase I clinical trials and proven to be safe. However, the immunogenicity and efficacy of these low seroprevalence vectors are reported to be lower in comparison to more prevalent HAd5. These results are very concerning and warrant further investigation to find the reasons for the poor performance of these vectors. The nAb and T cells against HAd5 do not cross react with HAd35 but nAbs and T cells against another common serotype, HAd2, cross react with HAd35 and reduce the immunogenicity and efficacy of the HAd35 vectors [188, 189].
To avoid the cross-reactive immunity due to closely related serotypes of Ad, more genetically distant Ad serotypes including animal and bird Ad were developed as viral vectors. Among non-human adenovirus vectors, chimpanzee-derived adenovirus vector (ChAd) is the most widely used. In comparison to HAd, the nAbs against ChAd have been found to be less prevalent. For example, nAbs against ChAd7 were detected in only 15% of American, European, Chinese, and African population [186]. Similarly, nAbs against ChAd6 are also low in these populations except Africans, which have about 40% ChAd6-specific nAbs [81, 186]. Several chimpanzee adenoviral vector-based vaccines, such as ChAd7 for Ebola virus, ChAd6 for rabies, and ChAd6, ChAd7, and ChAd9 for malaria, have shown high efficacy in animal models [190]. Furthermore, ChAd63-based malaria and ChAd3-based hepatitis C virus vaccines have shown to be safe and highly immunogenic in phase I clinical trial [191, 192]. Despite low seroprevalence of ChAd vectors in humans, pre-existing cross-reactive T cells against many conserved viral antigens are still a major concern. The HAd-induced ChAd cross-reactive T cells have been reported against ChAd6, ChAd7, ChAd24, ChAd32, and ChAd68 [22, 80, 89, 90]. The negative effects of these cross-reactive T cells on ChAd have been demonstrated in several animal models [22, 89]. The impact of the pre-existing cross-reactive T cells could be far greater in the clinical setting where humans are repeatedly exposed to various serotypes of adenovirus and carry a far broader diversity and a higher frequency of cross-reactive T cells.
Apart from rare human and chimpanzee adenoviruses, several other adenoviruses derived from animals such as bovine, porcine, ovine, canine, and fowl are also being explored for vector development [151, 193, 194, 195]. The human population lack nAbs against these adenoviruses, and therefore, the vectors derived from these adenoviruses could be more efficacious in comparison to HAd and ChAd. The mouse models with experimentally induced pre-existing immunity by the administration of HAd vector demonstrated a lack of nAbs and CD4+ T cells against PAd3 and BAd3 [18]. Furthermore, BAd3- or PAd3-based influenza virus vaccine demonstrated high efficacy even in the presence of pre-existing HAd5 immunity. There was also no effect of pre-existing HAd5 immunity on transgene expression, immunogenicity, and efficacy in animal models. However, their potential benefits still need to be proven in humans.
Several studies have reported that different routes of immunizations can negate the detrimental effect of pre-existing immunity. This outcome could be at least partly due to evasion of tissue-resident Ad-specific T cells when using different routes of immunization. Tissue-resident CD8 memory T cells remain confined to a specific tissue. As such, they are not systemic and do not prevent Ad vector infection in distant tissues. These tissue-resident T cells are induced by tissue-derived migratory dendritic cells during priming, which activate T cells with specific tissue-homing molecules [196, 197, 198]. In a non-human primate model, HAd5-induced protective immune responses by intranasal/intratracheal immunization were not affected by pre-existing HAd5 immunity that had been induced by intramuscular administration of an unrelated HAd5 vector [199]. Although this strategy has shown promising results in animal models, it has not been verified in humans. This strategy is however restricted by limited routes feasible for administration in humans. Moreover, the nAbs induced by adenoviral infection or adenoviral vector-based vaccination can be detected in any part of the body, which may affect the transgene expression and immune responses irrespective of the alternative route used for subsequent adenovector administration. However, nAbs are generally present in blood and are in most cases not cross-reactive to different serotypes or subtypes and Ads from different host species [200].
Another strategy to avoid pre-existing adenovector immunity involves the use of heterologous prime-boost regimens. In this strategy, the priming and boosting are done by using different antigen delivery vehicle and/or vectors derived from either different serotypes of the same species or vectors from completely different host species, for example, priming with DNA and boosting with HAd5 or priming with ChAd68 and boosting with ChAd1 [201]. Studies have shown that the heterologous prime-boost induces more robust immune responses compared to single vaccination or homologous prime-boost immunizations. The cellular immune responses induced by DNA prime and HAd boost were not affected by pre-existing HAd5 immunity. These findings were further confirmed in a clinical trial. Another preclinical study involving
Adenoviral antigens induce robust antibody and T cell immune responses. Recent studies have shown that adenoviral-derived epitopes can dominate over the transgene-derived epitopes and hinder the induction of transgene-specific immunity. This impairment of transgene-specific immune responses in naive vaccinees is due to immune competition. Epitopes derived from an adenovirus vector were shown to inhibit the induction of HIV GagL85-93-specific CD8+ T cells [205]. This study demonstrated that competition occurs at the level of responding CD8+ T cells, and co-immunization with an interleukin 2-encoding plasmid restored GagL85-93-specific CD8+ T cell responses in the presence of an adenoviral hexon486-494 epitope. The IL2, however, could not restore GagL85-93 responsiveness in Ad-based immunization, likely due to the presence of other epitopes in the Ad vector [206]. Another study demonstrated that plasmid DNA, but not adenovirus vector-encoding hepatitis B surface antigen (HBsAg), primed CD8 T cells against subdominant HBsAg epitopes [207]. These studies suggest that adenoviral antigen-specific T-cell immunity is primed efficiently during adenoviral vector-based immunization, which can limit the immunogenicity of adenoviral vector-encoded transgenic antigens. These studies highlight the need for modifications of the vector or the transgene used in immunization to circumvent or dominate over the adenoviral vector-specific epitopes and induce more effective transgene-specific immunity.
We discovered an unusual and interesting phenomenon that non-recombinant HAd5 vector induces robust cross-reactive immune responses toward hepatitis C virus (HCV) antigens [91]. Upon further investigation, we found that adenoviral proteins contain extensive homologies with various peptide epitopes derived from HCV antigens. These observations led us to investigate the adenoviral vector-induced HCV cross-reactive immune responses in detail in both mice and humans. In mice, we demonstrated that Ad vector alone can induce potent, broad anti-HCV cross-reactive immunity that can significantly reduce viral load upon challenge with infectious chimeric Vaccinia-HCV. Furthermore, we also detected HCV cross-reactive antibodies and HCV antigen-dependent expression of IFN-γ in T cells from a cohort of HCV-naïve but Ad-immune human individuals. Previous studies have also reported that one pathogen can induce cross-reactive immunity against an unrelated pathogen [91, 208]. This kind of immunity is known as heterologous immunity. Heterologous immunity is a double-edged sword, which can modulate the breadth of the T cell repertoire, influence the memory T cell pool and/or the immune dominance of a specific epitope, and lead to enhanced or diminished immune responses against a pathogen. These observations have significant clinical implications on natural history, immunopathogenesis, and disease outcome in HCV infection. The widespread use of adenoviral vectors in mass vaccination programs might change the immune hierarchy and natural T cell responses against HCV antigens and deviate and/or alter the incidence of HCV infection and immune pathogenesis in an at-risk population. However, a careful evaluation of adenoviral-induced cross-reactive immune responses and their impact on HCV immunity and immunopathology is needed to more accurately ascertain the impact of this phenomenon.
Since their first use as gene delivery vehicles, adenoviral vectors have been extensively studied in a number of applications and have improved substantially over time. Issues such as toxicity, pre-existing immunity in humans, and challenges in construction are continually being addressed. More recently, outbreaks of newly emerging infectious diseases, such as SARS, Ebola, and Zika, and the continuing threat of bioterrorism have increased the requirement of novel vaccine platforms which can be designed and produced in large scale within a short period of time. Adenoviral vectors, due to their versatility, ease of construction, adeptness to rapid mass production, and induction of robust transgene-specific humoral and cellular immune responses, have proven to be valuable in the development of vaccines for emerging viral infectious diseases. Furthermore, extensive knowledge about the adenoviral vector biology and the induced immune responses in animals have tremendously helped in developing effective vaccine candidates against several viral pathogens, which have progressed to advanced clinical stages. The adenoviruses are now at the forefront of vaccinology and have shown huge potential in both pre-clinical and clinical studies for HIV, malaria, Ebola virus, and Zika virus vaccines. Apart from infectious disease, adenoviral vectors have been approved for human use as cancer and gene therapy. Therefore, adenoviral vectors have opened new avenues in gene delivery, vaccine antigen delivery, and cancer molecular therapy.
We acknowledge Bharti Singh for designing and creating figures for this chapter. This work was supported by the Canadian Institutes of Health Research (CIHR) operating grant to BA (MOP 79327).
The authors SS, BA, and RK are co-inventors of a patent on adenoviral vector-based method of inducing immune responses against hepatitis C virus.
IntechOpen books are available online by accessing all published content on a chapter level.
",metaTitle:"Access policy",metaDescription:"IntechOpen books are available online by accessing all published content on a chapter level",metaKeywords:null,canonicalURL:null,contentRaw:'[{"type":"htmlEditorComponent","content":"All IntechOpen published chapters are available OPEN ACCESS can be read without the requirement for registration of any kind, immediately upon publication, without any barrier.
\\n\\nThe HTML version, as well as the PDF version of publications dated before 2012 that are accessible through a reader, are available to readers with no restriction.
\\n\\nThe full content of chapters can be read, copied and printed from the link location of the chapter and these actions are not limited or restricted in any way.
\\n\\nRegistration is requested only to download the PDF of the chapter. There are no subscription fees and there is no charge to user groups.
\\n\\nIntechOpen chapters are distributed under CC BY 3.0 licences allowing users to “copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship...” and there is no non-commercial restriction.
\\n\\nAuthors may post published works to any repository or website with no delay, and Authors and Editors of IntechOpen books have direct access to the PDF of the full book.
\\n\\nAll published content can be crawled for indexing. Full text and metadata may be accessed with instructions publicly posted.
\\n\\nAll IntechOpen books are indexed in CLOCKSS and preservation of access to published content is clearly indicated.
\\n\\nPolicy last updated: 2021-02-26
\\n"}]'},components:[{type:"htmlEditorComponent",content:"All IntechOpen published chapters are available OPEN ACCESS can be read without the requirement for registration of any kind, immediately upon publication, without any barrier.
\n\nThe HTML version, as well as the PDF version of publications dated before 2012 that are accessible through a reader, are available to readers with no restriction.
\n\nThe full content of chapters can be read, copied and printed from the link location of the chapter and these actions are not limited or restricted in any way.
\n\nRegistration is requested only to download the PDF of the chapter. There are no subscription fees and there is no charge to user groups.
\n\nIntechOpen chapters are distributed under CC BY 3.0 licences allowing users to “copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship...” and there is no non-commercial restriction.
\n\nAuthors may post published works to any repository or website with no delay, and Authors and Editors of IntechOpen books have direct access to the PDF of the full book.
\n\nAll published content can be crawled for indexing. Full text and metadata may be accessed with instructions publicly posted.
\n\nAll IntechOpen books are indexed in CLOCKSS and preservation of access to published content is clearly indicated.
\n\nPolicy last updated: 2021-02-26
\n"}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5818},{group:"region",caption:"Middle and South America",value:2,count:5287},{group:"region",caption:"Africa",value:3,count:1757},{group:"region",caption:"Asia",value:4,count:10539},{group:"region",caption:"Australia and Oceania",value:5,count:909},{group:"region",caption:"Europe",value:6,count:15929}],offset:12,limit:12,total:119317},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{sort:"dateEndThirdStepPublish",topicId:"9"},books:[{type:"book",id:"10519",title:"Middleware Architecture",subtitle:null,isOpenForSubmission:!0,hash:"c326d436ae0f4c508849d2336dbdfb48",slug:null,bookSignature:"Dr. Mehdia Ajana El Khaddar",coverURL:"https://cdn.intechopen.com/books/images_new/10519.jpg",editedByType:null,editors:[{id:"26677",title:"Dr.",name:"Mehdia",surname:"Ajana El Khaddar",slug:"mehdia-ajana-el-khaddar",fullName:"Mehdia Ajana El Khaddar"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10695",title:"Computational Fluid Dynamics",subtitle:null,isOpenForSubmission:!0,hash:"1f8fd29e4b72dbfe632f47840b369b11",slug:null,bookSignature:"Dr. Suvanjan Bhattacharyya",coverURL:"https://cdn.intechopen.com/books/images_new/10695.jpg",editedByType:null,editors:[{id:"233630",title:"Dr.",name:"Suvanjan",surname:"Bhattacharyya",slug:"suvanjan-bhattacharyya",fullName:"Suvanjan Bhattacharyya"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10651",title:"Machine Learning - Algorithms, Models and Applications",subtitle:null,isOpenForSubmission:!0,hash:"6208156401c496e0a4ca5ff4265324cc",slug:null,bookSignature:"Prof. Jaydip Sen",coverURL:"https://cdn.intechopen.com/books/images_new/10651.jpg",editedByType:null,editors:[{id:"4519",title:"Prof.",name:"Jaydip",surname:"Sen",slug:"jaydip-sen",fullName:"Jaydip Sen"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10692",title:"Critical Systems - Towards Antifragility",subtitle:null,isOpenForSubmission:!0,hash:"78d284ad921e9677830ef0335b1f1276",slug:null,bookSignature:"Prof. Darrell Mann",coverURL:"https://cdn.intechopen.com/books/images_new/10692.jpg",editedByType:null,editors:[{id:"297423",title:"Prof.",name:"Darrell",surname:"Mann",slug:"darrell-mann",fullName:"Darrell Mann"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10691",title:"Intelligent and Futuristic Computer Animation",subtitle:null,isOpenForSubmission:!0,hash:"5496e567e838f1eaeafba5f9a776b13a",slug:null,bookSignature:"Prof. Ahmad Hoirul Basori and Dr. Andi Besse Firdausiah Mansur",coverURL:"https://cdn.intechopen.com/books/images_new/10691.jpg",editedByType:null,editors:[{id:"13394",title:"Prof.",name:"Ahmad Hoirul",surname:"Basori",slug:"ahmad-hoirul-basori",fullName:"Ahmad Hoirul Basori"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10859",title:"Data Mining",subtitle:null,isOpenForSubmission:!0,hash:"63a4e514e537d3962cf53ef1c6b9d5eb",slug:null,bookSignature:"Prof. Ciza Thomas",coverURL:"https://cdn.intechopen.com/books/images_new/10859.jpg",editedByType:null,editors:[{id:"43680",title:"Prof.",name:"Ciza",surname:"Thomas",slug:"ciza-thomas",fullName:"Ciza Thomas"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10857",title:"Augmented Reality",subtitle:null,isOpenForSubmission:!0,hash:"5d66e2c09cddac7cc377ffb103aa7ef9",slug:null,bookSignature:"Dr. Dragan Mladen Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/10857.jpg",editedByType:null,editors:[{id:"101330",title:"Dr.",name:"Dragan",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10653",title:"Optimization Algorithms",subtitle:null,isOpenForSubmission:!0,hash:"3cf7194a8c120e74db9dd632b9affb83",slug:null,bookSignature:"Prof. Nodari Vakhania",coverURL:"https://cdn.intechopen.com/books/images_new/10653.jpg",editedByType:null,editors:[{id:"202585",title:"Prof.",name:"Nodari",surname:"Vakhania",slug:"nodari-vakhania",fullName:"Nodari Vakhania"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10858",title:"MOOC (Massive Open Online Courses)",subtitle:null,isOpenForSubmission:!0,hash:"d32f86793bc72dde32532f509b1ec5b0",slug:null,bookSignature:"Dr. Dragan Mladen Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/10858.jpg",editedByType:null,editors:[{id:"101330",title:"Dr.",name:"Dragan",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:27},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:8},{group:"topic",caption:"Business, Management and Economics",value:7,count:3},{group:"topic",caption:"Chemistry",value:8,count:11},{group:"topic",caption:"Computer and Information Science",value:9,count:9},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:10},{group:"topic",caption:"Engineering",value:11,count:24},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:4},{group:"topic",caption:"Materials Science",value:14,count:7},{group:"topic",caption:"Mathematics",value:15,count:3},{group:"topic",caption:"Medicine",value:16,count:47},{group:"topic",caption:"Neuroscience",value:18,count:3},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:3},{group:"topic",caption:"Physics",value:20,count:4},{group:"topic",caption:"Psychology",value:21,count:4},{group:"topic",caption:"Robotics",value:22,count:2},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:2}],offset:12,limit:12,total:9},popularBooks:{featuredBooks:[{type:"book",id:"8472",title:"Bioactive Compounds in Nutraceutical and Functional Food for Good Human Health",subtitle:null,isOpenForSubmission:!1,hash:"8855452919b8495810ef8e88641feb20",slug:"bioactive-compounds-in-nutraceutical-and-functional-food-for-good-human-health",bookSignature:"Kavita Sharma, Kanchan Mishra, Kula Kamal Senapati and Corina Danciu",coverURL:"https://cdn.intechopen.com/books/images_new/8472.jpg",editors:[{id:"197731",title:"Dr.",name:"Kavita",middleName:null,surname:"Sharma",slug:"kavita-sharma",fullName:"Kavita Sharma"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9685",title:"Agroecosystems",subtitle:"Very Complex Environmental Systems",isOpenForSubmission:!1,hash:"c44f7b43a9f9610c243dc32300d37df6",slug:"agroecosystems-very-complex-environmental-systems",bookSignature:"Marcelo L. Larramendy and Sonia Soloneski",coverURL:"https://cdn.intechopen.com/books/images_new/9685.jpg",editors:[{id:"14764",title:"Dr.",name:"Marcelo L.",middleName:null,surname:"Larramendy",slug:"marcelo-l.-larramendy",fullName:"Marcelo L. Larramendy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8564",title:"Cell Interaction",subtitle:"Molecular and Immunological Basis for Disease Management",isOpenForSubmission:!1,hash:"98d7f080d80524285f091e72a8e92a6d",slug:"cell-interaction-molecular-and-immunological-basis-for-disease-management",bookSignature:"Bhawana Singh",coverURL:"https://cdn.intechopen.com/books/images_new/8564.jpg",editors:[{id:"315192",title:"Dr.",name:"Bhawana",middleName:null,surname:"Singh",slug:"bhawana-singh",fullName:"Bhawana Singh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9629",title:"Electroencephalography",subtitle:"From Basic Research to Clinical Applications",isOpenForSubmission:!1,hash:"8147834b6c6deeeec40f407c71ad60b4",slug:"electroencephalography-from-basic-research-to-clinical-applications",bookSignature:"Hideki Nakano",coverURL:"https://cdn.intechopen.com/books/images_new/9629.jpg",editors:[{id:"196461",title:"Prof.",name:"Hideki",middleName:null,surname:"Nakano",slug:"hideki-nakano",fullName:"Hideki Nakano"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9161",title:"Frailty in the Elderly",subtitle:"Understanding and Managing Complexity",isOpenForSubmission:!1,hash:"a4f0f2fade8fb8ba35c405f5ad31a823",slug:"frailty-in-the-elderly-understanding-and-managing-complexity",bookSignature:"Sara Palermo",coverURL:"https://cdn.intechopen.com/books/images_new/9161.jpg",editors:[{id:"233998",title:"Ph.D.",name:"Sara",middleName:null,surname:"Palermo",slug:"sara-palermo",fullName:"Sara Palermo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8760",title:"Structure Topology and Symplectic Geometry",subtitle:null,isOpenForSubmission:!1,hash:"8974840985ec3652492c83e20233bf02",slug:"structure-topology-and-symplectic-geometry",bookSignature:"Kamal Shah and Min Lei",coverURL:"https://cdn.intechopen.com/books/images_new/8760.jpg",editors:[{id:"231748",title:"Dr.",name:"Kamal",middleName:null,surname:"Shah",slug:"kamal-shah",fullName:"Kamal Shah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"2160",title:"MATLAB",subtitle:"A Fundamental Tool for Scientific Computing and Engineering Applications - Volume 1",isOpenForSubmission:!1,hash:"dd9c658341fbd264ed4f8d9e6aa8ca29",slug:"matlab-a-fundamental-tool-for-scientific-computing-and-engineering-applications-volume-1",bookSignature:"Vasilios N. Katsikis",coverURL:"https://cdn.intechopen.com/books/images_new/2160.jpg",editors:[{id:"12289",title:"Prof.",name:"Vasilios",middleName:"N.",surname:"Katsikis",slug:"vasilios-katsikis",fullName:"Vasilios Katsikis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3568",title:"Recent Advances in Plant in vitro Culture",subtitle:null,isOpenForSubmission:!1,hash:"830bbb601742c85a3fb0eeafe1454c43",slug:"recent-advances-in-plant-in-vitro-culture",bookSignature:"Annarita Leva and Laura M. R. Rinaldi",coverURL:"https://cdn.intechopen.com/books/images_new/3568.jpg",editors:[{id:"142145",title:"Dr.",name:"Annarita",middleName:null,surname:"Leva",slug:"annarita-leva",fullName:"Annarita Leva"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7031",title:"Liver Pathology",subtitle:null,isOpenForSubmission:!1,hash:"631321b0565459ed0175917f1c8c727f",slug:"liver-pathology",bookSignature:"Vijay Gayam and Omer Engin",coverURL:"https://cdn.intechopen.com/books/images_new/7031.jpg",editors:[{id:"273100",title:"Dr.",name:"Vijay",middleName:null,surname:"Gayam",slug:"vijay-gayam",fullName:"Vijay Gayam"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3560",title:"Advances in Landscape Architecture",subtitle:null,isOpenForSubmission:!1,hash:"a20614517ec5f7e91188fe8e42832138",slug:"advances-in-landscape-architecture",bookSignature:"Murat Özyavuz",coverURL:"https://cdn.intechopen.com/books/images_new/3560.jpg",editors:[{id:"93073",title:"Dr.",name:"Murat",middleName:null,surname:"Ozyavuz",slug:"murat-ozyavuz",fullName:"Murat Ozyavuz"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8511",title:"Cyberspace",subtitle:null,isOpenForSubmission:!1,hash:"8c1cdeb133dbe6cc1151367061c1bba6",slug:"cyberspace",bookSignature:"Evon Abu-Taieh, Abdelkrim El Mouatasim and Issam H. Al Hadid",coverURL:"https://cdn.intechopen.com/books/images_new/8511.jpg",editors:[{id:"223522",title:"Dr.",name:"Evon",middleName:"M.O.",surname:"Abu-Taieh",slug:"evon-abu-taieh",fullName:"Evon Abu-Taieh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5319},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"8472",title:"Bioactive Compounds in Nutraceutical and Functional Food for Good Human Health",subtitle:null,isOpenForSubmission:!1,hash:"8855452919b8495810ef8e88641feb20",slug:"bioactive-compounds-in-nutraceutical-and-functional-food-for-good-human-health",bookSignature:"Kavita Sharma, Kanchan Mishra, Kula Kamal Senapati and Corina Danciu",coverURL:"https://cdn.intechopen.com/books/images_new/8472.jpg",editors:[{id:"197731",title:"Dr.",name:"Kavita",middleName:null,surname:"Sharma",slug:"kavita-sharma",fullName:"Kavita Sharma"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9685",title:"Agroecosystems",subtitle:"Very Complex Environmental Systems",isOpenForSubmission:!1,hash:"c44f7b43a9f9610c243dc32300d37df6",slug:"agroecosystems-very-complex-environmental-systems",bookSignature:"Marcelo L. Larramendy and Sonia Soloneski",coverURL:"https://cdn.intechopen.com/books/images_new/9685.jpg",editors:[{id:"14764",title:"Dr.",name:"Marcelo L.",middleName:null,surname:"Larramendy",slug:"marcelo-l.-larramendy",fullName:"Marcelo L. Larramendy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8564",title:"Cell Interaction",subtitle:"Molecular and Immunological Basis for Disease Management",isOpenForSubmission:!1,hash:"98d7f080d80524285f091e72a8e92a6d",slug:"cell-interaction-molecular-and-immunological-basis-for-disease-management",bookSignature:"Bhawana Singh",coverURL:"https://cdn.intechopen.com/books/images_new/8564.jpg",editors:[{id:"315192",title:"Dr.",name:"Bhawana",middleName:null,surname:"Singh",slug:"bhawana-singh",fullName:"Bhawana Singh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9629",title:"Electroencephalography",subtitle:"From Basic Research to Clinical Applications",isOpenForSubmission:!1,hash:"8147834b6c6deeeec40f407c71ad60b4",slug:"electroencephalography-from-basic-research-to-clinical-applications",bookSignature:"Hideki Nakano",coverURL:"https://cdn.intechopen.com/books/images_new/9629.jpg",editors:[{id:"196461",title:"Prof.",name:"Hideki",middleName:null,surname:"Nakano",slug:"hideki-nakano",fullName:"Hideki Nakano"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8760",title:"Structure Topology and Symplectic Geometry",subtitle:null,isOpenForSubmission:!1,hash:"8974840985ec3652492c83e20233bf02",slug:"structure-topology-and-symplectic-geometry",bookSignature:"Kamal Shah and Min Lei",coverURL:"https://cdn.intechopen.com/books/images_new/8760.jpg",editors:[{id:"231748",title:"Dr.",name:"Kamal",middleName:null,surname:"Shah",slug:"kamal-shah",fullName:"Kamal Shah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9161",title:"Frailty in the Elderly",subtitle:"Understanding and Managing Complexity",isOpenForSubmission:!1,hash:"a4f0f2fade8fb8ba35c405f5ad31a823",slug:"frailty-in-the-elderly-understanding-and-managing-complexity",bookSignature:"Sara Palermo",coverURL:"https://cdn.intechopen.com/books/images_new/9161.jpg",editors:[{id:"233998",title:"Ph.D.",name:"Sara",middleName:null,surname:"Palermo",slug:"sara-palermo",fullName:"Sara Palermo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"2160",title:"MATLAB",subtitle:"A Fundamental Tool for Scientific Computing and Engineering Applications - Volume 1",isOpenForSubmission:!1,hash:"dd9c658341fbd264ed4f8d9e6aa8ca29",slug:"matlab-a-fundamental-tool-for-scientific-computing-and-engineering-applications-volume-1",bookSignature:"Vasilios N. Katsikis",coverURL:"https://cdn.intechopen.com/books/images_new/2160.jpg",editors:[{id:"12289",title:"Prof.",name:"Vasilios",middleName:"N.",surname:"Katsikis",slug:"vasilios-katsikis",fullName:"Vasilios Katsikis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7031",title:"Liver Pathology",subtitle:null,isOpenForSubmission:!1,hash:"631321b0565459ed0175917f1c8c727f",slug:"liver-pathology",bookSignature:"Vijay Gayam and Omer Engin",coverURL:"https://cdn.intechopen.com/books/images_new/7031.jpg",editors:[{id:"273100",title:"Dr.",name:"Vijay",middleName:null,surname:"Gayam",slug:"vijay-gayam",fullName:"Vijay Gayam"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3568",title:"Recent Advances in Plant in vitro Culture",subtitle:null,isOpenForSubmission:!1,hash:"830bbb601742c85a3fb0eeafe1454c43",slug:"recent-advances-in-plant-in-vitro-culture",bookSignature:"Annarita Leva and Laura M. R. Rinaldi",coverURL:"https://cdn.intechopen.com/books/images_new/3568.jpg",editors:[{id:"142145",title:"Dr.",name:"Annarita",middleName:null,surname:"Leva",slug:"annarita-leva",fullName:"Annarita Leva"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"9515",title:"Update in Geriatrics",subtitle:null,isOpenForSubmission:!1,hash:"913e16c0ae977474b283bbd4269564c8",slug:"update-in-geriatrics",bookSignature:"Somchai Amornyotin",coverURL:"https://cdn.intechopen.com/books/images_new/9515.jpg",editedByType:"Edited by",editors:[{id:"185484",title:"Prof.",name:"Somchai",middleName:null,surname:"Amornyotin",slug:"somchai-amornyotin",fullName:"Somchai Amornyotin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9021",title:"Novel Perspectives of Stem Cell Manufacturing and Therapies",subtitle:null,isOpenForSubmission:!1,hash:"522c6db871783d2a11c17b83f1fd4e18",slug:"novel-perspectives-of-stem-cell-manufacturing-and-therapies",bookSignature:"Diana Kitala and Ana Colette Maurício",coverURL:"https://cdn.intechopen.com/books/images_new/9021.jpg",editedByType:"Edited by",editors:[{id:"203598",title:"Ph.D.",name:"Diana",middleName:null,surname:"Kitala",slug:"diana-kitala",fullName:"Diana Kitala"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7030",title:"Satellite Systems",subtitle:"Design, Modeling, Simulation and Analysis",isOpenForSubmission:!1,hash:"b9db6d2645ef248ceb1b33ea75f38e88",slug:"satellite-systems-design-modeling-simulation-and-analysis",bookSignature:"Tien Nguyen",coverURL:"https://cdn.intechopen.com/books/images_new/7030.jpg",editedByType:"Edited by",editors:[{id:"210657",title:"Dr.",name:"Tien M.",middleName:"Manh",surname:"Nguyen",slug:"tien-m.-nguyen",fullName:"Tien M. Nguyen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10413",title:"A Collection of Papers on Chaos Theory and Its Applications",subtitle:null,isOpenForSubmission:!1,hash:"900b71b164948830fec3d6254b7881f7",slug:"a-collection-of-papers-on-chaos-theory-and-its-applications",bookSignature:"Paul Bracken and Dimo I. Uzunov",coverURL:"https://cdn.intechopen.com/books/images_new/10413.jpg",editedByType:"Edited by",editors:[{id:"92883",title:"Prof.",name:"Paul",middleName:null,surname:"Bracken",slug:"paul-bracken",fullName:"Paul Bracken"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9154",title:"Spinal Deformities in Adolescents, Adults and Older Adults",subtitle:null,isOpenForSubmission:!1,hash:"313f1dffa803b60a14ff1e6966e93d91",slug:"spinal-deformities-in-adolescents-adults-and-older-adults",bookSignature:"Josette Bettany-Saltikov and Gokulakannan Kandasamy",coverURL:"https://cdn.intechopen.com/books/images_new/9154.jpg",editedByType:"Edited by",editors:[{id:"94802",title:"Dr.",name:"Josette",middleName:null,surname:"Bettany-Saltikov",slug:"josette-bettany-saltikov",fullName:"Josette Bettany-Saltikov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8148",title:"Investment Strategies in Emerging New Trends in Finance",subtitle:null,isOpenForSubmission:!1,hash:"3b714d96a68d2acdfbd7b50aba6504ca",slug:"investment-strategies-in-emerging-new-trends-in-finance",bookSignature:"Reza Gharoie Ahangar and Asma Salman",coverURL:"https://cdn.intechopen.com/books/images_new/8148.jpg",editedByType:"Edited by",editors:[{id:"91081",title:"Dr.",name:"Reza",middleName:null,surname:"Gharoie Ahangar",slug:"reza-gharoie-ahangar",fullName:"Reza Gharoie Ahangar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10201",title:"Post-Transition Metals",subtitle:null,isOpenForSubmission:!1,hash:"cc7f53ff5269916e3ce29f65a51a87ae",slug:"post-transition-metals",bookSignature:"Mohammed Muzibur Rahman, Abdullah Mohammed Asiri, Anish Khan, Inamuddin and Thamer Tabbakh",coverURL:"https://cdn.intechopen.com/books/images_new/10201.jpg",editedByType:"Edited by",editors:[{id:"24438",title:"Prof.",name:"Mohammed Muzibur",middleName:null,surname:"Rahman",slug:"mohammed-muzibur-rahman",fullName:"Mohammed Muzibur Rahman"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9959",title:"Biomedical Signal and Image Processing",subtitle:null,isOpenForSubmission:!1,hash:"22b87a09bd6df065d78c175235d367c8",slug:"biomedical-signal-and-image-processing",bookSignature:"Yongxia Zhou",coverURL:"https://cdn.intechopen.com/books/images_new/9959.jpg",editedByType:"Edited by",editors:[{id:"259308",title:"Dr.",name:"Yongxia",middleName:null,surname:"Zhou",slug:"yongxia-zhou",fullName:"Yongxia Zhou"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8472",title:"Bioactive Compounds in Nutraceutical and Functional Food for Good Human Health",subtitle:null,isOpenForSubmission:!1,hash:"8855452919b8495810ef8e88641feb20",slug:"bioactive-compounds-in-nutraceutical-and-functional-food-for-good-human-health",bookSignature:"Kavita Sharma, Kanchan Mishra, Kula Kamal Senapati and Corina Danciu",coverURL:"https://cdn.intechopen.com/books/images_new/8472.jpg",editedByType:"Edited by",editors:[{id:"197731",title:"Dr.",name:"Kavita",middleName:null,surname:"Sharma",slug:"kavita-sharma",fullName:"Kavita Sharma"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8760",title:"Structure Topology and Symplectic Geometry",subtitle:null,isOpenForSubmission:!1,hash:"8974840985ec3652492c83e20233bf02",slug:"structure-topology-and-symplectic-geometry",bookSignature:"Kamal Shah and Min Lei",coverURL:"https://cdn.intechopen.com/books/images_new/8760.jpg",editedByType:"Edited by",editors:[{id:"231748",title:"Dr.",name:"Kamal",middleName:null,surname:"Shah",slug:"kamal-shah",fullName:"Kamal Shah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"197",title:"Physical Medicine and Rehabilitation",slug:"physical-medicine-and-rehabilitation",parent:{title:"Medicine",slug:"medicine"},numberOfBooks:34,numberOfAuthorsAndEditors:760,numberOfWosCitations:639,numberOfCrossrefCitations:412,numberOfDimensionsCitations:949,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"physical-medicine-and-rehabilitation",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"9483",title:"Pain Management",subtitle:"Practices, Novel Therapies and Bioactives",isOpenForSubmission:!1,hash:"864679ec29988a68364151a4df2511a0",slug:"pain-management-practices-novel-therapies-and-bioactives",bookSignature:"Viduranga Yashasvi Waisundara, Ines Banjari and Jelena Balkić",coverURL:"https://cdn.intechopen.com/books/images_new/9483.jpg",editedByType:"Edited by",editors:[{id:"194281",title:"Dr.",name:"Viduranga Yashasvi",middleName:null,surname:"Waisundara",slug:"viduranga-yashasvi-waisundara",fullName:"Viduranga Yashasvi Waisundara"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editedByType:"Edited by",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9839",title:"Outdoor Recreation",subtitle:"Physiological and Psychological Effects on Health",isOpenForSubmission:!1,hash:"5f5a0d64267e32567daffa5b0c6a6972",slug:"outdoor-recreation-physiological-and-psychological-effects-on-health",bookSignature:"Hilde G. Nielsen",coverURL:"https://cdn.intechopen.com/books/images_new/9839.jpg",editedByType:"Edited by",editors:[{id:"158692",title:"Ph.D.",name:"Hilde G.",middleName:null,surname:"Nielsen",slug:"hilde-g.-nielsen",fullName:"Hilde G. Nielsen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9153",title:"Sports, Health and Exercise Medicine",subtitle:null,isOpenForSubmission:!1,hash:"366cfd9d5b01961dff4e4172896b1955",slug:"sports-health-and-exercise-medicine",bookSignature:"Samuel Honório, Marco Batista, João Serrano and Maria-Raquel G. Silva",coverURL:"https://cdn.intechopen.com/books/images_new/9153.jpg",editedByType:"Edited by",editors:[{id:"230170",title:"Ph.D.",name:"Samuel",middleName:null,surname:"Honório",slug:"samuel-honorio",fullName:"Samuel Honório"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7375",title:"Medical Robotics",subtitle:"New Achievements",isOpenForSubmission:!1,hash:"f24f06bf5980967a1ea36afe23fc0b02",slug:"medical-robotics-new-achievements",bookSignature:"Serdar Küçük and Abdullah Erdem Canda",coverURL:"https://cdn.intechopen.com/books/images_new/7375.jpg",editedByType:"Edited by",editors:[{id:"5424",title:"Dr.",name:"Serdar",middleName:null,surname:"Küçük",slug:"serdar-kucuk",fullName:"Serdar Küçük"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8335",title:"Effective Prevention and Treatment of Substance Use Disorders for Racial and Ethnic Minorities",subtitle:null,isOpenForSubmission:!1,hash:"ca6c7d5d975b1fa9ce320b1162b0dad6",slug:"effective-prevention-and-treatment-of-substance-use-disorders-for-racial-and-ethnic-minorities",bookSignature:"Erick Guerrero and Tenie Khachikian",coverURL:"https://cdn.intechopen.com/books/images_new/8335.jpg",editedByType:"Edited by",editors:[{id:"294761",title:"Dr.",name:"Erick",middleName:null,surname:"Guerrero",slug:"erick-guerrero",fullName:"Erick Guerrero"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7178",title:"Prosthesis",subtitle:null,isOpenForSubmission:!1,hash:"87ab135eeaa8424520cff806439e32a2",slug:"prosthesis",bookSignature:"Ramana Vinjamuri",coverURL:"https://cdn.intechopen.com/books/images_new/7178.jpg",editedByType:"Edited by",editors:[{id:"196746",title:"Dr.",name:"Ramana",middleName:null,surname:"Vinjamuri",slug:"ramana-vinjamuri",fullName:"Ramana Vinjamuri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7949",title:"Cardiorespiratory Fitness",subtitle:null,isOpenForSubmission:!1,hash:"fd6d8d7ee62bc8d443de2c5150c00535",slug:"cardiorespiratory-fitness",bookSignature:"Hasan Sözen",coverURL:"https://cdn.intechopen.com/books/images_new/7949.jpg",editedByType:"Edited by",editors:[{id:"161402",title:"Dr.",name:"Hasan",middleName:null,surname:"Sözen",slug:"hasan-sozen",fullName:"Hasan Sözen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7701",title:"Assistive and Rehabilitation Engineering",subtitle:null,isOpenForSubmission:!1,hash:"4191b744b8af3b17d9a80026dcb0617f",slug:"assistive-and-rehabilitation-engineering",bookSignature:"Yves Rybarczyk",coverURL:"https://cdn.intechopen.com/books/images_new/7701.jpg",editedByType:"Edited by",editors:[{id:"72920",title:"Prof.",name:"Yves",middleName:"Philippe",surname:"Rybarczyk",slug:"yves-rybarczyk",fullName:"Yves Rybarczyk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7879",title:"Spinal Cord Injury Therapy",subtitle:null,isOpenForSubmission:!1,hash:"674d4925395d0e0c564f092bda8c6482",slug:"spinal-cord-injury-therapy",bookSignature:"Antonio Ibarra, Elisa García-Vences and Gabriel Guízar-Sahagún",coverURL:"https://cdn.intechopen.com/books/images_new/7879.jpg",editedByType:"Edited by",editors:[{id:"72488",title:"Dr.",name:"José Juan Antonio",middleName:null,surname:"Ibarra Arias",slug:"jose-juan-antonio-ibarra-arias",fullName:"José Juan Antonio Ibarra Arias"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7897",title:"From Conventional to Innovative Approaches for Pain Treatment",subtitle:null,isOpenForSubmission:!1,hash:"b919454f06566215ea6a94c2d45239cc",slug:"from-conventional-to-innovative-approaches-for-pain-treatment",bookSignature:"Marco Cascella",coverURL:"https://cdn.intechopen.com/books/images_new/7897.jpg",editedByType:"Edited by",editors:[{id:"199335",title:"Dr.",name:"Marco",middleName:null,surname:"Cascella",slug:"marco-cascella",fullName:"Marco Cascella"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7540",title:"Different Areas of Physiotherapy",subtitle:null,isOpenForSubmission:!1,hash:"a73ff9538d7b2ff3aab93e411b669463",slug:"different-areas-of-physiotherapy",bookSignature:"Mintaze Kerem Gunel",coverURL:"https://cdn.intechopen.com/books/images_new/7540.jpg",editedByType:"Edited by",editors:[{id:"98035",title:"Prof.",name:"Mintaze",middleName:null,surname:"Kerem Gunel",slug:"mintaze-kerem-gunel",fullName:"Mintaze Kerem Gunel"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:34,mostCitedChapters:[{id:"28453",doi:"10.5772/28383",title:"The Application of Medical Infrared Thermography in Sports Medicine",slug:"the-application-of-medical-infrared-thermography-in-sports-medicine",totalDownloads:10517,totalCrossrefCites:22,totalDimensionsCites:57,book:{slug:"an-international-perspective-on-topics-in-sports-medicine-and-sports-injury",title:"An International Perspective on Topics in Sports Medicine and Sports Injury",fullTitle:"An International Perspective on Topics in Sports Medicine and Sports Injury"},signatures:"Carolin Hildebrandt, Karlheinz Zeilberger, Edward Francis John Ring and Christian Raschner",authors:[{id:"73700",title:"Dr.",name:"Carolin",middleName:null,surname:"Hildebrandt",slug:"carolin-hildebrandt",fullName:"Carolin Hildebrandt"},{id:"119056",title:"Dr.",name:"Christian",middleName:null,surname:"Raschner",slug:"christian-raschner",fullName:"Christian Raschner"},{id:"119058",title:"Dr.",name:"Karlheinz",middleName:null,surname:"Zeilberger",slug:"karlheinz-zeilberger",fullName:"Karlheinz Zeilberger"},{id:"119059",title:"Prof.",name:"Edward Francis John",middleName:null,surname:"Ring",slug:"edward-francis-john-ring",fullName:"Edward Francis John Ring"}]},{id:"19652",doi:"10.5772/20931",title:"Drilling of Bone: Practicality, Limitations and Complications Associated with Surgical Drill-Bits",slug:"drilling-of-bone-practicality-limitations-and-complications-associated-with-surgical-drill-bits",totalDownloads:12702,totalCrossrefCites:23,totalDimensionsCites:46,book:{slug:"biomechanics-in-applications",title:"Biomechanics in Applications",fullTitle:"Biomechanics in Applications"},signatures:"Nicky Bertollo and William Robert Walsh",authors:[{id:"32461",title:"Prof.",name:"William",middleName:null,surname:"Walsh",slug:"william-walsh",fullName:"William Walsh"},{id:"41089",title:"Dr.",name:"Nicky",middleName:null,surname:"Bertollo",slug:"nicky-bertollo",fullName:"Nicky Bertollo"}]},{id:"44692",doi:"10.5772/55461",title:"Iron Supplementation and Physical Performance",slug:"iron-supplementation-and-physical-performance",totalDownloads:2924,totalCrossrefCites:1,totalDimensionsCites:34,book:{slug:"current-issues-in-sports-and-exercise-medicine",title:"Current Issues in Sports and Exercise Medicine",fullTitle:"Current Issues in Sports and Exercise Medicine"},signatures:"Chariklia K. Deli, Ioannis G. Fatouros, Yiannis Koutedakis and\nAthanasios Z. Jamurtas",authors:[{id:"74567",title:"Dr.",name:"Athanasios",middleName:null,surname:"Jamurtas",slug:"athanasios-jamurtas",fullName:"Athanasios Jamurtas"},{id:"136569",title:"Dr.",name:"Ioannis",middleName:null,surname:"Fatouros",slug:"ioannis-fatouros",fullName:"Ioannis Fatouros"},{id:"161217",title:"M.Sc.",name:"Chariklia",middleName:"K",surname:"Deli",slug:"chariklia-deli",fullName:"Chariklia Deli"},{id:"167822",title:"Prof.",name:"Yiannis",middleName:null,surname:"Koutedakis",slug:"yiannis-koutedakis",fullName:"Yiannis Koutedakis"}]}],mostDownloadedChaptersLast30Days:[{id:"66378",title:"Reactive Astrocyte Gliosis: Production of Inhibitory Molecules",slug:"reactive-astrocyte-gliosis-production-of-inhibitory-molecules",totalDownloads:1463,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"spinal-cord-injury-therapy",title:"Spinal Cord Injury Therapy",fullTitle:"Spinal Cord Injury Therapy"},signatures:"Mohammad Taghi Joghataei, Fereshteh Azedi and Soraya Mehrabi",authors:[{id:"283292",title:"Ph.D. Student",name:"Fereshteh",middleName:null,surname:"Azedi",slug:"fereshteh-azedi",fullName:"Fereshteh Azedi"},{id:"283692",title:"Dr.",name:"Mohammad Taghi",middleName:null,surname:"Joghataei",slug:"mohammad-taghi-joghataei",fullName:"Mohammad Taghi Joghataei"},{id:"305689",title:"Dr.",name:"Soraya",middleName:null,surname:"Mehrabi",slug:"soraya-mehrabi",fullName:"Soraya Mehrabi"}]},{id:"40388",title:"Autonomic Regulation in Musculoskeletal Pain",slug:"autonomic-regulation-in-musculoskeletal-pain",totalDownloads:3601,totalCrossrefCites:0,totalDimensionsCites:3,book:{slug:"pain-in-perspective",title:"Pain in Perspective",fullTitle:"Pain in Perspective"},signatures:"David M. Hallman and Eugene Lyskov",authors:[{id:"142718",title:"Ph.D. Student",name:"David",middleName:"Michael",surname:"Hallman",slug:"david-hallman",fullName:"David Hallman"},{id:"148936",title:"Dr.",name:"Eugene",middleName:null,surname:"Lyskov",slug:"eugene-lyskov",fullName:"Eugene Lyskov"}]},{id:"62969",title:"Non-Pharmacological Pain Management",slug:"non-pharmacological-pain-management",totalDownloads:1768,totalCrossrefCites:2,totalDimensionsCites:2,book:{slug:"pain-management-in-special-circumstances",title:"Pain Management in Special Circumstances",fullTitle:"Pain Management in Special Circumstances"},signatures:"Ahmed El Geziry, Yasser Toble, Fathi Al Kadhi, Muhammad Pervaiz\nand Mohammad Al Nobani",authors:null},{id:"73348",title:"The Role of Cupping Therapy in Pain Management: A Literature Review",slug:"the-role-of-cupping-therapy-in-pain-management-a-literature-review",totalDownloads:213,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"pain-management-practices-novel-therapies-and-bioactives",title:"Pain Management",fullTitle:"Pain Management - Practices, Novel Therapies and Bioactives"},signatures:"Asma Al-Shidhani and Abdulaziz Al-Mahrezi",authors:[{id:"248467",title:"Dr.",name:"Abdulaziz",middleName:null,surname:"Al-Mahrezi",slug:"abdulaziz-al-mahrezi",fullName:"Abdulaziz Al-Mahrezi"},{id:"322652",title:"Dr.",name:"Asma",middleName:null,surname:"Al-Shidhani",slug:"asma-al-shidhani",fullName:"Asma Al-Shidhani"}]},{id:"47090",title:"Functional Electrical Stimulation in Paraplegia",slug:"functional-electrical-stimulation-in-paraplegia",totalDownloads:3980,totalCrossrefCites:0,totalDimensionsCites:4,book:{slug:"topics-in-paraplegia",title:"Topics in Paraplegia",fullTitle:"Topics in Paraplegia"},signatures:"Aris Papachristos",authors:[{id:"170551",title:"Dr.",name:"Aris",middleName:null,surname:"Papachristos",slug:"aris-papachristos",fullName:"Aris Papachristos"}]},{id:"73273",title:"Amputation Pain Management",slug:"amputation-pain-management",totalDownloads:290,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"pain-management-practices-novel-therapies-and-bioactives",title:"Pain Management",fullTitle:"Pain Management - Practices, Novel Therapies and Bioactives"},signatures:"Melinda S. Seering and Sangini Punia",authors:[{id:"323090",title:"Dr.",name:"Melinda S.",middleName:null,surname:"Seering",slug:"melinda-s.-seering",fullName:"Melinda S. Seering"},{id:"329349",title:"Dr.",name:"Sangini",middleName:null,surname:"Punia",slug:"sangini-punia",fullName:"Sangini Punia"}]},{id:"51945",title:"Neurophysiological Effects of Exercise",slug:"neurophysiological-effects-of-exercise",totalDownloads:1819,totalCrossrefCites:0,totalDimensionsCites:1,book:{slug:"fitness-medicine",title:"Fitness Medicine",fullTitle:"Fitness Medicine"},signatures:"Selma Cırrık and Gulay Hacioglu",authors:[{id:"188611",title:"Dr.",name:"Selma",middleName:null,surname:"Cırrık",slug:"selma-cirrik",fullName:"Selma Cırrık"},{id:"193887",title:"Dr.",name:"Gülay",middleName:null,surname:"Hacıoğlu",slug:"gulay-hacioglu",fullName:"Gülay Hacıoğlu"}]},{id:"63463",title:"Clinical Classification of Cerebral Palsy",slug:"clinical-classification-of-cerebral-palsy",totalDownloads:1750,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"cerebral-palsy-clinical-and-therapeutic-aspects",title:"Cerebral Palsy",fullTitle:"Cerebral Palsy - Clinical and Therapeutic Aspects"},signatures:"Christian Chukwukere Ogoke",authors:[{id:"250398",title:"Dr.",name:"Christian",middleName:"Chukwukere",surname:"Ogoke",slug:"christian-ogoke",fullName:"Christian Ogoke"}]},{id:"53866",title:"Physical Therapy in Patients with Cancer",slug:"physical-therapy-in-patients-with-cancer",totalDownloads:3056,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"clinical-physical-therapy",title:"Clinical Physical Therapy",fullTitle:"Clinical Physical Therapy"},signatures:"Shinichiro Morishita and Atsuhiro Tsubaki",authors:[{id:"139514",title:"Ph.D.",name:"Shinichiro",middleName:null,surname:"Morishita",slug:"shinichiro-morishita",fullName:"Shinichiro Morishita"},{id:"202889",title:"Dr.",name:"Atsuhiro",middleName:null,surname:"Tsubaki",slug:"atsuhiro-tsubaki",fullName:"Atsuhiro Tsubaki"}]},{id:"75480",title:"Nutraceutical Alternatives to Pharmaceutical Analgesics in Osteoarthritis",slug:"nutraceutical-alternatives-to-pharmaceutical-analgesics-in-osteoarthritis",totalDownloads:70,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"pain-management-practices-novel-therapies-and-bioactives",title:"Pain Management",fullTitle:"Pain Management - Practices, Novel Therapies and Bioactives"},signatures:"Shane M. Heffernan and Gillian E. Conway",authors:[{id:"322446",title:"Dr.",name:"Shane M.",middleName:"M",surname:"Heffernan",slug:"shane-m.-heffernan",fullName:"Shane M. Heffernan"},{id:"341083",title:"Dr.",name:"Gillian E.",middleName:null,surname:"Conway",slug:"gillian-e.-conway",fullName:"Gillian E. Conway"}]}],onlineFirstChaptersFilter:{topicSlug:"physical-medicine-and-rehabilitation",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[],offset:0,limit:8,total:null},route:{name:"profile.detail",path:"/profiles/128188/urmas-peterson",hash:"",query:{},params:{id:"128188",slug:"urmas-peterson"},fullPath:"/profiles/128188/urmas-peterson",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()